{"content":"<li class=\"n-box-item date-title\" data-end=\"1575953999\" data-start=\"1575867600\" data-txt=\"Monday, December 23, 2019\">Monday, December  9, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3525000\" data-ts=\"1575949307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABR\" target=\"_blank\">ABR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525000-arbor-realty-trust-prices-upsized-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arbor Realty Trust prices upsized equity offering</a></h4><ul> <li>Arbor Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/ABR' title='Arbor Realty Trust, Inc.'>ABR</a>) prices upsized public offering of 6.5M common shares for gross proceeds of ~$91.9M.</li><li>Closing date is December 12, 2019.</li>   <li>Plans to grant greenshoe option for up to an additional 975,000 shares.</li><li>Intends to use the net proceeds from the offering to make investments relating to its business and for general corporate purposes.</li><li>Also plans to use some of the net proceeds to purchase a total of 650,000 shares, or 747,500 shares if the underwriters exercise in full their option to purchase additional shares of the company's common stock from its CEO, Arbor Commercial Mortgage LLC, and/or estate planning family vehicle established by the company's CEO at the same price the underwriters will purchase the shares in the offering.</li><li>ABR  <font color=\"red\">-3.5%</font> after hours to  $14.25</li><li>Source: <a href=\"https://seekingalpha.com/pr/17722795-arbor-realty-trust-inc-announces-pricing-of-upsized-public-offering-of-common-stock\" target=\"_blank\">Press Release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525000\" data-linked=\"Arbor Realty Trust prices upsized equity offering\" data-tweet=\"$ABR - Arbor Realty Trust prices upsized equity offering https://seekingalpha.com/news/3525000-arbor-realty-trust-prices-upsized-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3525000-arbor-realty-trust-prices-upsized-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524993\" data-ts=\"1575934610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFRX\" target=\"_blank\">CFRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524993-contrafect-offering-shares-sets-pfizer-purchase-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ContraFect offering shares, sets Pfizer purchase deal</a></h4><ul>   <li>ContraFect (NASDAQ:<a href='https://seekingalpha.com/symbol/CFRX' title='ContraFect Corporation'>CFRX</a>) will <a href=\"https://seekingalpha.com/pr/17722569-contrafect-corporation-announces-proposed-public-offering-of-common-stock-and-concurrent\" target=\"_blank\">offer shares</a> via Maxim Group alongside a private placement of common stock to Pfizer.</li>    <li>Pfizer has entered a purchase agreement to buy up to $3M in ContraFect shares at the offering price.</li>    <li>The company has also issued program updates via an <a href=\"https://seekingalpha.com/filing/4729525\" target=\"_blank\">SEC filing</a>.</li>    <li>Shares are <font color=\"green\">up 12.7%</font> after hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524993\" data-linked=\"ContraFect offering shares, sets Pfizer purchase deal\" data-tweet=\"$CFRX - ContraFect offering shares, sets Pfizer purchase deal https://seekingalpha.com/news/3524993-contrafect-offering-shares-sets-pfizer-purchase-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3524993-contrafect-offering-shares-sets-pfizer-purchase-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524987\" data-ts=\"1575931821\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCYX\" target=\"_blank\">SCYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524987-scynexisminus-18-after-launching-stock-warrant-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCYNEXIS -18% after launching stock/warrant offering</a></h4><ul>   <li>SCYNEXIS (NASDAQ:<a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a>) is <font color=\"red\">17.8% lower</font> postmarket after <a href=\"https://seekingalpha.com/pr/17722564-scynexis-announces-launch-of-public-offering-of-common-stock-and-warrants\" target=\"_blank\">launching an offering</a> of common stock and warrants.</li>    <li>H.C. Wainwright is sole book-runner for the offering.</li>    <li>The company expects to grant the underwriter a 30-day greenshoe option to buy up to an additional 15% of shares at the offering terms.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524987\" data-linked=\"SCYNEXIS -18% after launching stock/warrant offering\" data-tweet=\"$SCYX - SCYNEXIS -18% after launching stock/warrant offering https://seekingalpha.com/news/3524987-scynexisminus-18-after-launching-stock-warrant-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3524987-scynexisminus-18-after-launching-stock-warrant-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524980\" data-ts=\"1575930773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524980-mdb-gnw-sfix-and-casy-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MDB, GNW, SFIX and CASY among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/EQ' title='Equillium, Inc.'>EQ</a> <font color=\"green\">+17.3%</font>. <a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a> <font color=\"green\">+12.2%</font>. <a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a> <font color=\"green\">+10.1%</font>. <a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a> <font color=\"green\">+5.6%</font>. <a href='https://seekingalpha.com/symbol/GMDA' title='Gamida Cell Ltd.'>GMDA</a> <font color=\"green\">+4.0%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/LVGO' title='Livongo Health, Inc.'>LVGO</a> <font color=\"red\">-7.5%</font>. <a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a> <font color=\"red\">-6.3%. </font><a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color=\"red\">-4.5%</font>. <a href='https://seekingalpha.com/symbol/PHI' title='PLDT Inc.'>PHI</a> <font color=\"red\">-3.6%</font>. <a href='https://seekingalpha.com/symbol/CNST' title='Constellation Pharmaceuticals, Inc.'>CNST</a> <font color=\"red\">-3.1%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524980\" data-linked=\"MDB, GNW, SFIX and CASY among after hour movers\" data-tweet=\"$EQ $SFIX $GNW - MDB, GNW, SFIX and CASY among after hour movers https://seekingalpha.com/news/3524980-mdb-gnw-sfix-and-casy-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524980-mdb-gnw-sfix-and-casy-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524972\" data-ts=\"1575929680\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSN\" target=\"_blank\">PSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524972-parsonsplus-3_8-after-win-on-disa-seti-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Parsons +3.8% after win on DISA SETI deal</a></h4><ul>   <li>Parsons (NYSE:<a href='https://seekingalpha.com/symbol/PSN' title='Parsons Corporation'>PSN</a>) has won a <a href=\"https://seekingalpha.com/pr/17722605-parsons-wins-prime-position-on-7_5b-defense-information-technology-contract\" target=\"_blank\">prime position</a> on a SETI contract with the Defense Information Systems Agency.</li>    <li>Shares are <font color=\"green\">up 3.8%</font> after hours.</li>    <li>The contract is a $7.5B multiple-award, indefinite delivery/indefinite quantity deal.</li>    <li>It's targeted at disruptive innovation to enhance how warfighters engage with Defense Dept. information technology.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524972\" data-linked=\"Parsons +3.8% after win on DISA SETI deal\" data-tweet=\"$PSN - Parsons +3.8% after win on DISA SETI deal https://seekingalpha.com/news/3524972-parsonsplus-3_8-after-win-on-disa-seti-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3524972-parsonsplus-3_8-after-win-on-disa-seti-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524961\" data-ts=\"1575928243\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVGO\" target=\"_blank\">LVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524961-livongo-health-down-3-after-hours-on-shareholder-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Livongo Health down 3% after hours on shareholder offering</a></h4><ul><li>Livongo Health (NASDAQ:<a href='https://seekingalpha.com/symbol/LVGO' title='Livongo Health, Inc.'>LVGO</a>) slips <font color=\"red\">3%</font> after hours on light volume on the heels of a <a href=\"https://seekingalpha.com/pr/17722681-livongo-announces-launch-of-proposed-public-offering-selling-stockholders\" target=\"_blank\">public offering</a> of ~2.8M common shares by existing investors.</li><li>Underwriters' over-allotment is an additional ~417K shares.</li><li>The company will, of course, receive no proceeds from the offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524961\" data-linked=\"Livongo Health down 3% after hours on shareholder offering\" data-tweet=\"$LVGO - Livongo Health down 3% after hours on shareholder offering https://seekingalpha.com/news/3524961-livongo-health-down-3-after-hours-on-shareholder-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3524961-livongo-health-down-3-after-hours-on-shareholder-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524959\" data-ts=\"1575928022\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOL\" target=\"_blank\">TOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524959-toll-brothers-q4-eps-beats-sees-stronger-demand-in-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toll Brothers Q4 EPS beats; sees stronger demand in Q1</a></h4><ul><li>Toll Brothers (NYSE:<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers, Inc.'>TOL</a>) <a href=\"https://seekingalpha.com/pr/17722665-toll-brothers-reports-fy-2019-4th-quarter-results\" target=\"_blank\">fiscal Q4 EPS</a> of $1.41 beats the average analyst estimate of $1.31 and falls from $2.08 in the year-ago quarter.</li><li>Sees Q1 2020 deliveries of 1,650-1,850 units with an average price of $800K-$820K.</li><li>Sees Q1 adjusted home sales gross margin of ~21.25%, which it expects to be the low point of the year.</li><li>Toll <font color=\"green\">gains 3.9%</font> in after-hours trading.</li><li>Fiscal Q4 homebuilding deliveries were 2,672 units, down 1% Y/Y; home sales revenue of $2.29B fell 1% Y/Y.</li><li>Q4 adjusted home sales gross margin was 21.9%.</li><li>Backlog value at Q4 end was $5.26B, down 5%; units in backlog totaled 6,266, up 3%.</li><li>\"Building on steady improvement in buyer demand throughout the year, our fourth quarter contracts were up 18% in units and 12% in dollars, and our contracts per-community were up 10% compared to one year ago,\" said Toll Chairman and CEO Douglas C. Yearley, Jr. \"Through the first six weeks of fiscal 2020's first quarter, we have seen even stronger demand than the order growth of fiscal 2019\u2019s fourth quarter.\"</li><li><a href=\"https://www.tollbrothers.com/\" target=\"_blank\">Conference call </a>on Dec. 10 at 11:00 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524950-toll-brothers-eps-beats-0_10-beats-on-revenue\" target=\"_blank\">Toll Brothers EPS beats by $0.10, beats on revenue</a> (Dec. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3524959\" data-linked=\"Toll Brothers Q4 EPS beats; sees stronger demand in Q1\" data-tweet=\"$TOL - Toll Brothers Q4 EPS beats; sees stronger demand in Q1 https://seekingalpha.com/news/3524959-toll-brothers-q4-eps-beats-sees-stronger-demand-in-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3524959-toll-brothers-q4-eps-beats-sees-stronger-demand-in-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524957\" data-ts=\"1575927844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGN\" target=\"_blank\">REGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524957-regeneron-down-5-after-hours-on-possible-sale-of-sanofi-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regeneron down 5% after hours on possible sale of Sanofi stake</a></h4><ul><li>Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) slips <font color=\"red\">5%</font> after hours on light volume in reaction to reports that alliance partner Sanofi (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) may sell its stake in the biotech.</li><li>Per Regeneron's <a href=\"https://www.sec.gov/Archives/edgar/data/872589/000093041319001350/c92333_def14a.htm#x3_c92333a038\" target=\"_blank\">2019 proxy statement</a> (page 48) filed in April, Sanofi owned 23,523,269 shares representing a 21.8% stake.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524957\" data-linked=\"Regeneron down 5% after hours on possible sale of Sanofi stake\" data-tweet=\"$REGN $SNY - Regeneron down 5% after hours on possible sale of Sanofi stake https://seekingalpha.com/news/3524957-regeneron-down-5-after-hours-on-possible-sale-of-sanofi-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3524957-regeneron-down-5-after-hours-on-possible-sale-of-sanofi-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524948\" data-ts=\"1575927285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDB\" target=\"_blank\">MDB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524948-mongodbplus-7_6-after-q3-beat-strong-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MongoDB +7.6% after Q3 beat, strong guidance</a></h4><ul>   <li>MongoDB (NASDAQ:<a href='https://seekingalpha.com/symbol/MDB' title='MongoDB, Inc.'>MDB</a>) is <font color=\"green\">up 7.6%</font> postmarket after posting a better-than-expected loss in <a href=\"https://seekingalpha.com/news/3524919-mongodb-eps-beats-0_02-beats-on-revenue\" target=\"_blank\">Q3 earnings</a>, with growth paced by strong improvement in subscriptions.</li>    <li>Overall revenues rose 52.5% to $109.4M, and subscription growth was 56%, while services revenue grew 8%.</li>    <li>Gross profit of $79.3M marked a margin of 72%.</li>    <li>Net loss widened slightly on a non-GAAP basis, to $14.6M from a year-ago loss of $6.9M.</li>    <li>For Q4, it's guiding to revenue of $109M-$111M (above consensus for $105.6M) and EPS of -$0.29 to -$0.27 (better than consensus for -$0.30).</li>    <li>Cash use from operations was $11.5M, and free cash flow was negative $13.1M; liquidity was $426.4M at quarter's end.</li>    <li>For the full year, it's forecasting revenues of $407.2M-$409.2M (above expectations for $394.2M) and EPS of -$1.04 to -$1.02 (better than consensus for -$1.07).</li>    <li><a href=\"https://services.choruscall.com/links/mdb191209.html\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>   <li><a href=\"https://seekingalpha.com/pr/17722591-mongodb-inc-announces-third-quarter-fiscal-2020-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3524948\" data-linked=\"MongoDB +7.6% after Q3 beat, strong guidance\" data-tweet=\"$MDB - MongoDB +7.6% after Q3 beat, strong guidance https://seekingalpha.com/news/3524948-mongodbplus-7_6-after-q3-beat-strong-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3524948-mongodbplus-7_6-after-q3-beat-strong-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524947\" data-ts=\"1575927038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMC\" target=\"_blank\">WMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524947-western-asset-mortgage-re-opens-2022-notes-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Asset Mortgage re-opens 2022 notes offering</a></h4><ul><li>Western Asset Mortgage Capital (NYSE:<a href='https://seekingalpha.com/symbol/WMC' title='Western Asset Mortgage Capital Corporation'>WMC</a>)<font color=\"red\"> falls 1.8%</font> in after-hours trading after it begins an offering of 6.75% convertible senior notes due 2022.</li><li>The notes will be a further issuance of and form a single series with the $115M principal amount of 6.75% convertible senior notes due 2022 it issued in October 2017 and $40M more of notes issued in August 2019.</li><li>The company intends to use the net proceeds from the offering primarily for general corporate purposes, including to opportunistically invest in credit sensitive investments consisting of Residential Whole Loans, Commercial Loans and Non-Agency CMBS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524947\" data-linked=\"Western Asset Mortgage re-opens 2022 notes offering\" data-tweet=\"$WMC - Western Asset Mortgage re-opens 2022 notes offering https://seekingalpha.com/news/3524947-western-asset-mortgage-re-opens-2022-notes-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3524947-western-asset-mortgage-re-opens-2022-notes-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524945\" data-ts=\"1575926882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNST\" target=\"_blank\">CNST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524945-constellation-pharma-readies-equity-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Constellation Pharma readies equity offering; shares down 7% after hours</a></h4><ul><li>Constellation Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNST' title='Constellation Pharmaceuticals, Inc.'>CNST</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1434418/000119312519309197/d841609ds3asr.htm\" target=\"_blank\">prospectus </a>for an unspecified mixed shelf offering.</li><li>Shares are down <font color=\"red\">7%</font> after hours after dropping <font color=\"red\">17%</font> during the regular session. The stock is still up six-fold from late September, however.</li><li>At the end of September, it had $89.1M in quick assets while operations consumed $55.3M during the first three quarters of the year.</li><li><strong>Update</strong>: The company has launched a <a href=\"https://seekingalpha.com/pr/17722632-constellation-pharmaceuticals-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">public offering</a> of 4.75M common shares. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524945\" data-linked=\"Constellation Pharma readies equity offering; shares down 7% after hours\" data-tweet=\"$CNST - Constellation Pharma readies equity offering; shares down 7% after hours https://seekingalpha.com/news/3524945-constellation-pharma-readies-equity-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3524945-constellation-pharma-readies-equity-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524944\" data-ts=\"1575926799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASY\" target=\"_blank\">CASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524944-caseys-general-storesminus-4-after-sales-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Casey&#39;s General Stores -4% after sales miss</a></h4><ul> <li>Casey's General Stores (NASDAQ:<a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a>) reports same-store grocery sales were up 3.2% in <a href=\"https://investor.caseys.com/press-releases/press-release-details/2019/Caseys-Continues-Strong-Performance-In-Second-Quarter/default.aspx\" target=\"_blank\">FQ2</a> to edge the consensus estimate of +3.1%.</li> <li>Same-store fuel gallons were down 1.8% vs. -0.8% anticipated.</li> <li>Same-store prepared food and fountain sales were up 1.9% vs. +3.0% consensus.</li> <li>Fuel margin was 22.9% during the quarter and grocery margin was 33.3%.</li> <li>CEO update: \"We are optimistic about the new initiatives that will launch in the back half of fiscal 2020 and beyond, and believe they will continue to create additional shareholder value.\"</li> <li>CASY <font color=\"red\">-3.60% </font>AH to $169.00.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524942-caseys-general-stores-eps-beats-0_08-misses-on-revenue\" target=\"_blank\">Caseys General Stores EPS beats by $0.08, misses on revenue</a> (Dec. 9)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524944\" data-linked=\"Casey&#39;s General Stores -4% after sales miss\" data-tweet=\"$CASY - Casey&#39;s General Stores -4% after sales miss https://seekingalpha.com/news/3524944-caseys-general-storesminus-4-after-sales-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3524944-caseys-general-storesminus-4-after-sales-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524940\" data-ts=\"1575926578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EQ\" target=\"_blank\">EQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524940-equilliums-itolizumab-fast-trackd-for-lupus-nephritis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Equillium&#39;s itolizumab Fast Track&#39;d for lupus nephritis</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17722604-equillium-granted-u-s-fda-fast-track-designation-for-itolizumab-for-treatment-of-lupus\" target=\"_blank\">designates </a>Equillium's (NASDAQ:<a href='https://seekingalpha.com/symbol/EQ' title='Equillium, Inc.'>EQ</a>) <a href=\"https://clinicaltrials.gov/ct2/show/NCT04128579?term=nct04128579&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 1</a>-stage itolizumab for Fast Track review for the treatment of lupus nephritis.</li><li>Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524940\" data-linked=\"Equillium&#39;s itolizumab Fast Track&#39;d for lupus nephritis\" data-tweet=\"$EQ - Equillium&#39;s itolizumab Fast Track&#39;d for lupus nephritis https://seekingalpha.com/news/3524940-equilliums-itolizumab-fast-trackd-for-lupus-nephritis?source=tweet\" data-url=\"https://seekingalpha.com/news/3524940-equilliums-itolizumab-fast-trackd-for-lupus-nephritis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524938\" data-ts=\"1575926545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHWY\" target=\"_blank\">CHWY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524938-chewy-eps-misses-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chewy EPS misses by $0.04, beats on revenue</a></h4><ul><li>Chewy (NYSE:<a href='https://seekingalpha.com/symbol/CHWY' title='Chewy, Inc.'>CHWY</a>): Q3 GAAP EPS of -$0.20 <font color=\"red\">misses by $0.04</font>.</li><li>Revenue of $1.23B (+40.1% Y/Y) <font color=\"green\">beats by $30M</font>.</li><li>Shares <font color=\"green\">+1.78%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17722621-chewy-announces-third-quarter-2019-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3524938\" data-linked=\"Chewy EPS misses by $0.04, beats on revenue\" data-tweet=\"$CHWY - Chewy EPS misses by $0.04, beats on revenue https://seekingalpha.com/news/3524938-chewy-eps-misses-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3524938-chewy-eps-misses-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524937\" data-ts=\"1575926433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHWY\" target=\"_blank\">CHWY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524937-chewyplus-2-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chewy +2% after earnings</a></h4><ul>  <li>Chewy (NYSE:<a href='https://seekingalpha.com/symbol/CHWY' title='Chewy, Inc.'>CHWY</a>) gains after posting a narrower <a href=\"https://seekingalpha.com/pr/17722621-chewy-announces-third-quarter-2019-financial-results\" target=\"_blank\">Q3</a> adjusted EBITDA loss than anticipated (-$30.2M vs. -$35.9M consensus).</li>  <li>Chewy churned up sales growth of 40% for the quarter and gross margin improved 410 bps to 23.7% of sales.</li>  <li>Guidance from Chewy should be upcoming on the <a href=\"https://investor.chewy.com/news-and-events/events-and-presentations/event-details/2019/Chewy-Third-Quarter-2019-Earnings-Call/default.aspx\" target=\"_blank\">conference call</a> at 5:00 p.m.</li>  <li>Shares of Chewy are <font color=\"green\">up 1.55%</font> in AH trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524937\" data-linked=\"Chewy +2% after earnings\" data-tweet=\"$CHWY - Chewy +2% after earnings https://seekingalpha.com/news/3524937-chewyplus-2-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3524937-chewyplus-2-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524935\" data-ts=\"1575926412\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNG\" target=\"_blank\">UNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524935-natural-gas-hits-skids-on-warm-winter-weather-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas hits the skids on warm winter weather outlook</a></h4><ul><li>Natural gas futures (<a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a> <font color='red'>-4%</font>) for January delivery settled <font color=\"red\">-4.4%</font> to $2.232/MMBtu, after hitting their <a href=\"https://www.wsj.com/articles/warm-winter-weather-prompts-lower-natural-gas-price-forecasts-11575917524\" target=\"_blank\">lowest level since August</a> in early trading, on fears that warmer than normal winter weather will fail to drive enough demand to counter surging production.</li><li>A cold spell is expected to pass over the Midwest and east during the middle of the week, boosting demand for nat gas, but \"temperatures will warm back above normal across much of the U.S. next weekend with highs of 50s to 70s returning for a swing back to very light national demand,\" says NatGasWeather.com.</li><li>U.S. production averaged 96B cf/day at the end of November, up ~3B cf over the past 10 weeks, according to Tudor Pickering Holt, which also says it expects gas in storage to end winter 25% above the five-year average, pushing prices below $2//MMBtu in Q2 2020.</li><li>Natural gas-focused names finished mostly higher: <a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color=\"green\">+3.8%</font>, <a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color=\"green\">+5.4%</font>, <a href='https://seekingalpha.com/symbol/EQT' title='EQT Corporation'>EQT</a> <font color=\"green\">+1%</font>, <a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color=\"green\">+2.6%</font>, <a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a> <font color=\"green\">+17.3%</font>, <a href='https://seekingalpha.com/symbol/COG' title='Cabot Oil & Gas Corporation'>COG</a> <font color=\"green\">+0.2%</font>, <a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Company'>SWN</a> <font color=\"red\">-1.4%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Trust II - ProShares Ultra Bloomberg Natural Gas'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GASL' title='Direxion Daily Natural Gas Related Bull 3x Shares ETF'>GASL</a>, <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas'>KOLD</a>, <a href='https://seekingalpha.com/symbol/GASX' title='Direxion Daily Natural Gas Related Bear 3X Shares ETF'>GASX</a>, <a href='https://seekingalpha.com/symbol/UNL' title='United States 12 Month Natural Gas Fund, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/GAZB' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZB</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3524935\" data-linked=\"Natural gas hits the skids on warm winter weather outlook\" data-tweet=\"$UNG $CHK $RRC - Natural gas hits the skids on warm winter weather outlook https://seekingalpha.com/news/3524935-natural-gas-hits-skids-on-warm-winter-weather-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3524935-natural-gas-hits-skids-on-warm-winter-weather-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524933\" data-ts=\"1575926316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/A\" target=\"_blank\">A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524933-agilent-up-4-after-hours-on-pershing-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agilent up 4% after hours on Pershing stake</a></h4><ul><li>Agilent (NYSE:<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies, Inc.'>A</a>) is up <font color=\"green\">4%</font> after hours on modest volume in apparent reaction to a <a href=\"https://www.sec.gov/Archives/edgar/data/1336528/000117266119002404/xslForm13F_X01/infotable.xml\" target=\"_blank\">disclosure</a> by Bill Ackman's Pershing Square of a stake of ~2.9M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524933\" data-linked=\"Agilent up 4% after hours on Pershing stake\" data-tweet=\"$A - Agilent up 4% after hours on Pershing stake https://seekingalpha.com/news/3524933-agilent-up-4-after-hours-on-pershing-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3524933-agilent-up-4-after-hours-on-pershing-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524927\" data-ts=\"1575925887\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDMO\" target=\"_blank\">CDMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524927-avid-bioservices-eps-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avid Bioservices EPS beats by $0.03, beats on revenue</a></h4><ul><li>Avid Bioservices (NASDAQ:<a href='https://seekingalpha.com/symbol/CDMO' title='Avid Bioservices, Inc.'>CDMO</a>): Q2 GAAP EPS of -$0.03 <font color=\"green\">beats by $0.03</font>.</li><li>Revenue of $18.31M (+79.9% Y/Y) <font color=\"green\">beats by $3.97M</font>.</li><li>Shares <font color=\"green\">+5.64%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17722593-avid-bioservices-reports-financial-results-for-second-quarter-fiscal-2020-and-recent\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3524927\" data-linked=\"Avid Bioservices EPS beats by $0.03, beats on revenue\" data-tweet=\"$CDMO - Avid Bioservices EPS beats by $0.03, beats on revenue https://seekingalpha.com/news/3524927-avid-bioservices-eps-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3524927-avid-bioservices-eps-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524926\" data-ts=\"1575925882\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFIX\" target=\"_blank\">SFIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524926-stitch-fixplus-8-after-avoiding-red-ink\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stitch Fix +8% after avoiding red ink</a></h4><ul> <li>Stitch Fix (NASDAQ:<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a>) pops after topping estimates with both lines of its <a href=\"https://seekingalpha.com/pr/17722596-stitch-fix-announces-first-quarter-fiscal-year-2020-financial-results\" target=\"_blank\">FQ1</a> report off 21% sales growth.</li> <li>The retailer also posted EBITDA of $5.1M during the quarter vs. -$5.5M consensus.</li> <li>Stitch Fix's active client list rose 17% to 3.4M during the quarter.</li> <li>SFIX <font color=\"green\">+8.40%</font> AH to $27.08.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524922-stitch-fix-eps-beats-0_06-beats-on-revenue\" target=\"_blank\">Stitch Fix EPS beats by $0.06, beats on revenue</a> (Dec. 9)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524926\" data-linked=\"Stitch Fix +8% after avoiding red ink\" data-tweet=\"$SFIX - Stitch Fix +8% after avoiding red ink https://seekingalpha.com/news/3524926-stitch-fixplus-8-after-avoiding-red-ink?source=tweet\" data-url=\"https://seekingalpha.com/news/3524926-stitch-fixplus-8-after-avoiding-red-ink\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524924\" data-ts=\"1575925815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524924-ascena-retail-group-reports-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail Group reports Q1 results</a></h4><ul><li>Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a>): Q1 Non-GAAP EPS of $0.18; GAAP EPS of $0.16.</li><li>Revenue of $1.29B (-3.7% Y/Y)</li><li>Shares <font color=\"green\">+41.99%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17722594-ascena-retail-group-inc-announces-first-quarter-fiscal-2020-results-reports-income-per-share\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3524924\" data-linked=\"Ascena Retail Group reports Q1 results\" data-tweet=\"$ASNA - Ascena Retail Group reports Q1 results https://seekingalpha.com/news/3524924-ascena-retail-group-reports-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3524924-ascena-retail-group-reports-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524921\" data-ts=\"1575925737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBIO\" target=\"_blank\">MBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524921-mustang-bio-down-18-on-less-effect-of-gene-therapy-on-older-xscid-patients\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mustang Bio down 18% on less effect of gene therapy on older XSCID patients</a></h4><ul><li>Thinly traded Mustang Bio (<a href='https://seekingalpha.com/symbol/MBIO' title='Mustang Bio, Inc.'>MBIO</a> <font color=\"red\">-17.7%</font>) is down on almost 4x higher volume, albeit on turnover of less than 1M shares, in apparent reaction to <a href=\"https://ghr.nlm.nih.gov/condition/x-linked-severe-combined-immunodeficiency\" target=\"_blank\">updated data</a> from ongoing Phase 1/2 clinical trials evaluating lentiviral gene therapy MB-107 in patients with X-linked severe combined immunodeficiency &#40;XSCID&#41;, an inherited disorder also known as \"Bubble Boy Disease\" since it occurs almost exclusively in males who lack the necessary immune cells to fight infections. The results were presented as ASH in Orlando.</li><li>In the study being conducted at St. Jude Children's Hospital in Memphis, infants under the age of two showed \"robust\" stem cell recovery with 3-4 weeks post infusion without blood support. Nine participants who had been followed for more than three months achieved normal-for-age T-cell and NK-cell numbers within three-to-four months post treatment. Five were off IV immunoglobulin therapy and three of the five responded to vaccines.</li><li>Investors appear to be reacting to data from the second trial, being conducted at NIH in Bethesda, MD, in five older children and young adults with XSCID who received MB-107 as salvage therapy after haploidentical hematopoietic stem cell transplantation.</li><li>Patients required large quantities of vector due to the relative inefficient transduction of hematopoietic stem/progenitor cells which resulted in a relatively low vector copy number &#40;VCN&#41; in myeloid cells in some patients. This delayed immune cell recovery and failed to prevent persistent clinical disease, especially in the last patient treated. NIH refined the transduction procedure and incorporated enhancers which produced a more significant benefit by month 3.</li><li>Development is ongoing.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524921\" data-linked=\"Mustang Bio down 18% on less effect of gene therapy on older XSCID patients\" data-tweet=\"$MBIO - Mustang Bio down 18% on less effect of gene therapy on older XSCID patients https://seekingalpha.com/news/3524921-mustang-bio-down-18-on-less-effect-of-gene-therapy-on-older-xscid-patients?source=tweet\" data-url=\"https://seekingalpha.com/news/3524921-mustang-bio-down-18-on-less-effect-of-gene-therapy-on-older-xscid-patients\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524922\" data-ts=\"1575925674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFIX\" target=\"_blank\">SFIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524922-stitch-fix-eps-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stitch Fix EPS beats by $0.06, beats on revenue</a></h4><ul><li>Stitch Fix (NASDAQ:<a href='https://seekingalpha.com/symbol/SFIX' title='Stitch Fix, Inc.'>SFIX</a>): Q1 GAAP EPS of $0.00 <font color=\"green\">beats by $0.06</font>.</li><li>Revenue of $444.82M (+21.5% Y/Y) <font color=\"green\">beats by $3.65M</font>.</li><li>Shares <font color=\"green\">+7%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17722596-stitch-fix-announces-first-quarter-fiscal-year-2020-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3524922\" data-linked=\"Stitch Fix EPS beats by $0.06, beats on revenue\" data-tweet=\"$SFIX - Stitch Fix EPS beats by $0.06, beats on revenue https://seekingalpha.com/news/3524922-stitch-fix-eps-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3524922-stitch-fix-eps-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524920\" data-ts=\"1575925648\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLBS\" target=\"_blank\">GLBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524920-globus-maritime-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Globus Maritime reports Q3 results</a></h4><ul><li>Globus Maritime (NASDAQ:<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Limited'>GLBS</a>): Q3 GAAP EPS of $0.06.</li><li>Revenue of $4.95M (+1.9% Y/Y)</li><li>Shares <font color=\"green\">+4.3%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17722582-globus-maritime-limited-reports-financial-results-for-quarter-and-nine-month-period-ended\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3524920\" data-linked=\"Globus Maritime reports Q3 results\" data-tweet=\"$GLBS - Globus Maritime reports Q3 results https://seekingalpha.com/news/3524920-globus-maritime-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3524920-globus-maritime-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524906\" data-ts=\"1575923732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLEX\" target=\"_blank\">LLEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524906-lilis-energy-gets-nyse-american-listing-deficiency-notice\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lilis Energy gets NYSE American listing deficiency notice</a></h4><ul><li>Lilis Energy (<a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='red'>-14.3%</font>) says it received a deficiency letter from the NYSE American saying the company is <a href=\"https://seekingalpha.com/pr/17721199-lilis-energy-notified-of-nyse-american-listing-deficiency\" target=\"_blank\">no longer in compliance</a> with continued listing standards because the stock has been selling for a low price for a substantial time period.</li><li>LLEX must effect a reverse stock split or show sustained price improvement no later than June 3,  2020, according to the letter.</li><li><a href=\"https://seekingalpha.com/pr/17712930-lilis-energy-notified-of-nyse-american-listing-deficiency\" target=\"_blank\">Late last month</a>, LLEX disclosed it was told by the NYSE American that it was below compliance with listing standards because it had reported a stockholders' equity deficiency as of Sept. 30 and net losses in its five most recent fiscal years ended Dec. 31, 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524906\" data-linked=\"Lilis Energy gets NYSE American listing deficiency notice\" data-tweet=\"$LLEX - Lilis Energy gets NYSE American listing deficiency notice https://seekingalpha.com/news/3524906-lilis-energy-gets-nyse-american-listing-deficiency-notice?source=tweet\" data-url=\"https://seekingalpha.com/news/3524906-lilis-energy-gets-nyse-american-listing-deficiency-notice\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524904\" data-ts=\"1575923125\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AM\" target=\"_blank\">AM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524904-antero-midstream-maintained-buy-lower-pt-ladenburg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antero Midstream maintained Buy but with lower PT at Ladenburg</a></h4><ul><li>Antero Midstream (<a href='https://seekingalpha.com/symbol/AM' title='Antero Midstream Corporation'>AM</a> <font color='green'>+15.4%</font>) is <a href=\"https://thefly.com/thestreet/realmoney/index.php/AM;ARid3004149/AM;AR-Antero-Midstream-price-target-lowered-to--from--at-Ladenburg-\" target=\"_blank\">reiterated with a Buy rating</a> but with a reduced $8 price target, cut from $10, at Ladenburg after the company  <a href=\"https://seekingalpha.com/news/3524719-antero-resources-unveils-midstream-fee-reductions-asset-sale-program\" target=\"_blank\">announced</a> it would repurchase $100M of its shares from Antero Resources (<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a> <font color='green'>+17.8%</font>),  which AM estimated \"will result in $20M-plus in total dividend  savings in 2020.\"</li><li>Additionally, AM and AR agreed to a growth incentive fee program where AM will  provide fee reductions to AR in 2020-23, contingent upon  AR achieving growth targets on low pressure gathering  volumes.</li><li>Due to additional optimization of the midstream infrastructure buildout, AM said it is now targeting a 2020 capex program of $300M-$325M, a 22% reduction vs. the previous target.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524904\" data-linked=\"Antero Midstream maintained Buy but with lower PT at Ladenburg\" data-tweet=\"$AM $AR - Antero Midstream maintained Buy but with lower PT at Ladenburg https://seekingalpha.com/news/3524904-antero-midstream-maintained-buy-lower-pt-ladenburg?source=tweet\" data-url=\"https://seekingalpha.com/news/3524904-antero-midstream-maintained-buy-lower-pt-ladenburg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524903\" data-ts=\"1575922758\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTWO\" target=\"_blank\">TTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524903-take-two-sets-up-new-studio-building-bioshock-game\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Take-Two sets up new studio building &#39;BioShock&#39; game</a></h4><ul>   <li>Take-Two's (<a href=\"http://seekingalpha.com/symbol/TTWO\" target=\"_blank\">TTWO</a> <font color=\"red\">-2.8%</font>) 2K has formed a wholly owned studio, Cloud Chamber, which will be put to work on a new entry in the <a href=\"https://seekingalpha.com/pr/17721707-2k-announces-newly-formed-studio-cloud-chamber-developing-next-iteration-in-acclaimed\" target=\"_blank\"><i>BioShock</i> franchise</a>.</li>    <li>Cloud Chamber will build a team at two locations: 2K's San Francisco Bay-area headquarters, and in Montréal (the first Canadian office for a 2K studio).</li>    <li>Industry veteran Kelley Gilmore will be in charge, the first woman in 2K history to launch and lead a development studio.</li>    <li>Gilmore has named Ken Schachter as Cloud Chamber's studio manager in Montréal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524903\" data-linked=\"Take-Two sets up new studio building &#39;BioShock&#39; game\" data-tweet=\"$TTWO - Take-Two sets up new studio building &#39;BioShock&#39; game https://seekingalpha.com/news/3524903-take-two-sets-up-new-studio-building-bioshock-game?source=tweet\" data-url=\"https://seekingalpha.com/news/3524903-take-two-sets-up-new-studio-building-bioshock-game\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524895\" data-ts=\"1575921372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524895-optimizerx-leads-technology-gainers-progyny-and-icad-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OptimizeRx leads technology gainers; Progyny and iCAD among losers</a></h4><ul><li><b>Gainers:</b> OptimizeRx (NASDAQ:<a href='https://seekingalpha.com/symbol/OPRX' title='OptimizeRx Corporation'>OPRX</a>) <font color=\"green\">+15%</font>. SiTime (NASDAQ:<a href='https://seekingalpha.com/symbol/SITM' title='SiTime Corporation'>SITM</a>) <font color=\"green\">+14%</font>. LG Display (NYSE:<a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a>) <font color=\"green\">+10%</font>. Alithya Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ALYA' title='Alithya Group Inc.'>ALYA</a>) <font color=\"green\">+9%</font>. CyberOptics (NASDAQ:<a href='https://seekingalpha.com/symbol/CYBE' title='CyberOptics Corporation'>CYBE</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers:</b> NantHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/NH' title='NantHealth, Inc.'>NH</a>) <font color=\"red\">-12%</font>. Progyny (NASDAQ:<a href='https://seekingalpha.com/symbol/PGNY' title='Progyny, Inc.'>PGNY</a>) <font color=\"red\">-7%</font>. Jianpu Technology (NYSE:<a href='https://seekingalpha.com/symbol/JT' title='Jianpu Technology Inc.'>JT</a>) <font color=\"red\">-6%</font>. ACM Research (NASDAQ:<a href='https://seekingalpha.com/symbol/ACMR' title='ACM Research, Inc.'>ACMR</a>) <font color=\"red\">-6%</font>. iCAD (NASDAQ:<a href='https://seekingalpha.com/symbol/ICAD' title='iCAD, Inc.'>ICAD</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524895\" data-linked=\"OptimizeRx leads technology gainers; Progyny and iCAD among losers\" data-tweet=\"$OPRX $SITM $LPL - OptimizeRx leads technology gainers; Progyny and iCAD among losers https://seekingalpha.com/news/3524895-optimizerx-leads-technology-gainers-progyny-and-icad-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524895-optimizerx-leads-technology-gainers-progyny-and-icad-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524894\" data-ts=\"1575920719\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOS\" target=\"_blank\">KOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524894-kosmos-energy-hits-11-month-lows-on-tullows-troubles\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kosmos Energy hits 11-month lows on Tullow&#39;s troubles</a></h4><ul><li>Kosmos Energy (<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy Ltd.'>KOS</a> <font color='red'>-14.2%</font>) plunges to its lowest levels since January before rebounding a bit, following news that Tullow Oil reset guidance for FY 2020 production to 70K-80K bbl/day, compared with 87K bbl/day this year, and said performance has been <a href=\"https://seekingalpha.com/news/3524653-tullow-oil-tanks-after-ceo-resigns-dividend-suspended\" target=\"_blank\">significantly below expectations</a> at the TEN and Jubilee fields in Ghana.</li><li>KOS is active in Ghana and is a partner in production at the TEN and Jubilee fields.</li><li>The worry is that the problems at one of KOS's major partners could affect the company's cash generating assets, as KOS <a href=\"https://www.fool.com/investing/2019/12/09/shares-of-kosmos-energy-get-dragged-down-by-its-pa.aspx\" target=\"_blank\">needs to fund</a> its other offshore development  projects over the next few years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524894\" data-linked=\"Kosmos Energy hits 11-month lows on Tullow&#39;s troubles\" data-tweet=\"$KOS - Kosmos Energy hits 11-month lows on Tullow&#39;s troubles https://seekingalpha.com/news/3524894-kosmos-energy-hits-11-month-lows-on-tullows-troubles?source=tweet\" data-url=\"https://seekingalpha.com/news/3524894-kosmos-energy-hits-11-month-lows-on-tullows-troubles\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524892\" data-ts=\"1575919670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUN\" target=\"_blank\">HUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524892-huntsman-hiked-to-buy-citigroup-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huntsman hiked to Buy at Citigroup on valuation</a></h4><ul><li>Huntsman (<a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a> <font color='green'>+1.5%</font>) moves higher after Citigroup <a href=\"https://thefly.com/thestreet/realmoney/index.php/HUNid3003804/HUN-Huntsman-upgraded-to-Buy-from-Neutral-at-Citi\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $26 price target, anticipating a solid balance sheet after the expected $1.6B in net proceeds coming from the Indorama deal and a relatively inexpensive valuation.</li><li>Citi analyst P.J. Juvekar also says conversations with management have raised his confidence on HUN's acquisition execution toward growing specialties.</li><li>HUN targets 20%-plus returns for organic and greater than mid-teens for inorganic growth, Juvekar adds.</li><li>HUN's average <a href=\"https://seekingalpha.com/symbol/HUN/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, while both its <a href=\"https://seekingalpha.com/symbol/HUN/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/HUN/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524892\" data-linked=\"Huntsman hiked to Buy at Citigroup on valuation\" data-tweet=\"$HUN - Huntsman hiked to Buy at Citigroup on valuation https://seekingalpha.com/news/3524892-huntsman-hiked-to-buy-citigroup-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3524892-huntsman-hiked-to-buy-citigroup-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524891\" data-ts=\"1575919455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGN\" target=\"_blank\">REGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524891-regeneron-bispecific-antibody-shows-encouraging-action-in-early-stage-mm-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regeneron bispecific antibody shows encouraging action in early-stage MM study</a></h4><ul><li>Regeneron Pharmaceuticals (<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color=\"red\">-2.4%</font>) <a href=\"https://seekingalpha.com/pr/17721387-first-clinical-data-for-regn5458-bcmaxcd3-show-positive-preliminary-results-in-multiple\" target=\"_blank\">announces </a>positive initial data from an open-label <a href=\"https://clinicaltrials.gov/ct2/show/NCT03761108?intr=regn5458&amp;lead=regeneron&amp;phase=0&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 1/2 dose-escalation study</a> evaluating REGN5458 in multiple myeloma &#40;MM&#41; patients who have exhausted all therapeutic options. The results were presented at ASH in Orlando.</li><li>The overall response rate &#40;ORR&#41; in the first two dose arms was 57% (n=4/7), including a 75% ORR (n=3/4) in the higher dose (6 mg weekly) group. Two of the participants in the latter showed no cancer cells in their bone marrow.</li><li>On the safety front, no neurotoxicity, dose-limiting toxicities or treatment-related discontinuations were observed. The most common REGN5458-related adverse events were lymphopenia (71%), anemia (57%), thrombocytopenia (43%) and cytokine release syndrome (43%). Serious/life-threatening treatment-related adverse events were observed in five (71%) subjects, including lymphopenia (n=3), hypertension (n=2) and anemia, atrial fibrillation, fatigue, febrile neutropenia, pain in extremity, septic shock and thrombocytopenia (one each).</li><li>Additional data should be available in 2020.</li><li>REGN5458 is a BCMAxCD3 bispecific antibody designed to bind to BCMA (B-cell maturation antigen) and the CD3 receptor on T cells, bridging them together and activating cancer cell-killing activity of T cells. It is one of six bispecific antibodies that company has in clinical development.</li><li>The company has launched another <a href=\"https://clinicaltrials.gov/ct2/show/NCT04083534?intr=regn5459&amp;lead=regeneron&amp;phase=0&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 1</a> evaluating REGN5459, also a BCMAxCD3 bispecific but with differing binding characteristics, in relapsed/refractory MM.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524891\" data-linked=\"Regeneron bispecific antibody shows encouraging action in early-stage MM study\" data-tweet=\"$REGN - Regeneron bispecific antibody shows encouraging action in early-stage MM study https://seekingalpha.com/news/3524891-regeneron-bispecific-antibody-shows-encouraging-action-in-early-stage-mm-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3524891-regeneron-bispecific-antibody-shows-encouraging-action-in-early-stage-mm-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524886\" data-ts=\"1575918136\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524886-energy-materials-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <font color=\"green\">+21%</font>. Antero Midstream (NYSE:<a href='https://seekingalpha.com/symbol/AM' title='Antero Midstream Corporation'>AM</a>) <font color=\"green\">+15%</font>. KLX Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/KLXE' title='KLX Energy Services Holdings, Inc.'>KLXE</a>) <font color=\"green\">+14%</font>. Altus Midstream (NASDAQ:<a href='https://seekingalpha.com/symbol/ALTM' title='Altus Midstream Company'>ALTM</a>) <font color=\"green\">+9%</font>. EnLink Midstream (NYSE:<a href='https://seekingalpha.com/symbol/ENLC' title='EnLink Midstream, LLC'>ENLC</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Kosmos Energy (NYSE:<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy Ltd.'>KOS</a>) <font color=\"red\">-13%</font>. Synthesis Energy Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a>) <font color=\"red\">-8%</font>. Brigham Minerals (NYSE:<a href='https://seekingalpha.com/symbol/MNRL' title='Brigham Minerals, Inc.'>MNRL</a>) <font color=\"red\">-8%</font>. International Flavors &amp; Fragrances (NYSE:<a href='https://seekingalpha.com/symbol/IFF' title='International Flavors & Fragrances Inc.'>IFF</a>) <font color=\"red\">-6%</font>. Lightbridge (NASDAQ:<a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corporation'>LTBR</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524886\" data-linked=\"Energy/Materials  - Top 5 Gainers / Losers\" data-tweet=\"$AR $AM $KLXE - Energy/Materials - Top 5 Gainers / Losers https://seekingalpha.com/news/3524886-energy-materials-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524886-energy-materials-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524883\" data-ts=\"1575917080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DTIL\" target=\"_blank\">DTIL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524883-precision-bio-down-49-on-early-stage-car-t-data-in-nhl\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Precision Bio down 49% on early-stage CAR T data in NHL</a></h4><ul><li>Precision BioSciences (<a href='https://seekingalpha.com/symbol/DTIL' title='Precision BioSciences, Inc.'>DTIL</a> <font color=\"red\">-48.9%</font>) slumps on a 12x surge in volume in reaction to <a href=\"https://seekingalpha.com/pr/17721633-precision-biosciences-presents-updated-interim-clinical-data-ash-annual-meeting-from-relapsed\" target=\"_blank\">updated preliminary data</a> from from the NHL cohort in an ongoing <a href=\"https://clinicaltrials.gov/ct2/show/NCT03666000?lead=precision+biosciences&amp;phase=0&amp;draw=2&amp;rank=3\" target=\"_blank\">Phase 1 clinical trial</a> evaluating CAR T candidate PBCAR0191. The results were presented at ASH in Orlando.</li><li>The overall response rate &#40;ORR&#41; in patients with relapsed/refractory NHL was 66% (n=4/6), including one complete responder, but two other early responders progressed.</li><li>The ORR was 33% (n=1/3) at day 28+ in patients with relapsed/refractory B-cell precursor ALL. The response was complete. The two non-responders had poor prognoses at study entry.</li><li>On the safety front, no serious adverse events (AEs) or evidence of graft-versus-host disease was observed. There was one serious treatment-related AE (pain at the site of the tumor mass for one day following infusion) and one life-threatening treatment-related AE, lymphopenia (low level of lymphocytes), that lasted for seven days.</li><li>Investors may be judging the results compared to Bristol-Myers Squibb's lisocabtagene maraleucel (JCAR017) which <a href=\"https://seekingalpha.com/news/3524626-bristol-myers-car-t-successful-in-pivotal-nhl-study-four-deaths\" target=\"_blank\">demonstrated </a>a 73% ORR, including a 53% complete response rate, in patients treatment-resistant large B-cell lymphomas.</li><li>The company will host an investigator update this evening at 8:15 pm ET to discuss the data.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524883\" data-linked=\"Precision Bio down 49% on early-stage CAR T data in NHL\" data-tweet=\"$DTIL - Precision Bio down 49% on early-stage CAR T data in NHL https://seekingalpha.com/news/3524883-precision-bio-down-49-on-early-stage-car-t-data-in-nhl?source=tweet\" data-url=\"https://seekingalpha.com/news/3524883-precision-bio-down-49-on-early-stage-car-t-data-in-nhl\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524882\" data-ts=\"1575916265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524882-viacomcbs-explores-sale-of-ny-cbs-headquarters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ViacomCBS explores sale of NY CBS headquarters</a></h4><ul>    <li>ViacomCBS (<a href='https://seekingalpha.com/symbol/VIAC' title='ViacomCBS Inc.'>VIAC</a> <font color=\"red\">-1.5%</font>, <a href='https://seekingalpha.com/symbol/VIACA' title='ViacomCBS Inc.'>VIACA</a> <font color=\"red\">-3.2%</font>) will <a href=\"https://variety.com/2019/biz/news/viacomcbs-explore-sale-black-rock-cbs-headquarters-1203429865/\" target=\"_blank\">explore the sale</a> of the iconic \"Black Rock\" Manhattan CBS headquarters.</li>    <li>It's one of a number of real estate transactions the newly recombined company will consider, particularly \"non-core\" holdings, CEO Bob Bakish says. And it would look to perhaps use proceeds from such sales for stock repurchases.</li>    <li>Black Rock, on West 52nd Street, has been CBS HQ since opening in 1965.</li>    <li>CBS sold its Television City production facility last year in order to raise funds for content.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524882\" data-linked=\"ViacomCBS explores sale of NY CBS headquarters\" data-tweet=\"$VIAC $VIACA - ViacomCBS explores sale of NY CBS headquarters https://seekingalpha.com/news/3524882-viacomcbs-explores-sale-of-ny-cbs-headquarters?source=tweet\" data-url=\"https://seekingalpha.com/news/3524882-viacomcbs-explores-sale-of-ny-cbs-headquarters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524879\" data-ts=\"1575915702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524879-phcf-leads-financial-gainers-wei-and-ever-only-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PHCF leads financial gainers; WEI and EVER the only losers</a></h4><ul><li><b>Gainers:</b> Puhui Wealth Investment Management (NASDAQ:<a href='https://seekingalpha.com/symbol/PHCF' title='Puhui Wealth Investment Management Co., Ltd.'>PHCF</a>) <font color=\"green\">+19%</font>. Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='Bat Group, Inc.'>GLG</a>) <font color=\"green\">+12%</font>. At Home Group (NYSE:<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group Inc.'>HOME</a>) <font color=\"green\">+9%</font>. Texas Capital Bancshares (NASDAQ:<a href='https://seekingalpha.com/symbol/TCBI' title='Texas Capital Bancshares, Inc.'>TCBI</a>) <font color=\"green\">+8%</font>. Fangdd Network Group (NASDAQ:<a href='https://seekingalpha.com/symbol/DUO' title='Fangdd Network Group Ltd.'>DUO</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers:</b> Weidai (NYSE:<a href='https://seekingalpha.com/symbol/WEI' title='Weidai Ltd.'>WEI</a>) <font color=\"red\">-10%</font>. EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote, Inc.'>EVER</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524879\" data-linked=\"PHCF leads financial gainers; WEI and EVER the only losers\" data-tweet=\"$PHCF $GLG $HOME - PHCF leads financial gainers; WEI and EVER the only losers https://seekingalpha.com/news/3524879-phcf-leads-financial-gainers-wei-and-ever-only-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524879-phcf-leads-financial-gainers-wei-and-ever-only-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524878\" data-ts=\"1575915519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGT\" target=\"_blank\">TGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524878-target-wins-award-after-stellar-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Target wins award after stellar year</a></h4><ul><li>Target (<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a> <font color='green'>+1.6%</font>) is <a href=\"https://finance.yahoo.com/news/target-yahoo-finance-2019-company-of-the-year-050104286.html\" target=\"_blank\">named</a> Yahoo Finance's 2019 Company of the Year.</li><li>\"Despite a dizzying series of investments in stores, people, process and product over the past three years, profit margins have magically sprung to life,\" notes YF Editor Brian Sozzi.</li><li>Sizzling sales tallies have helped push shares of Target to a +88% YTD gain.</li><li>The <a href=\"https://seekingalpha.com/symbol/TGT/ratings/sell-side-ratings\" target=\"_blank\">average sell-side price target</a> on Target is $135.92, about 7% above the current share price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524878\" data-linked=\"Target wins award after stellar year\" data-tweet=\"$TGT - Target wins award after stellar year https://seekingalpha.com/news/3524878-target-wins-award-after-stellar-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3524878-target-wins-award-after-stellar-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524910\" data-ts=\"1575915010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTV\" target=\"_blank\">FTV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524910-fortive-grabs-upgrades-citi-credit-suisse\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortive grabs upgrades at Citi, Credit Suisse</a></h4><ul><li>Fortive (<a href='https://seekingalpha.com/symbol/FTV' title='Fortive Corporation'>FTV</a> <font color='green'>+1.8%</font>) jumps to its highest level since July after winning two sell-side upgrades, one from Citigroup and the other from Credit Suisse.</li><li><a href=\"https://thefly.com/thestreet/realmoney/index.php/FTV;MMMid3003858/FTV;MMM-Citi-upgrades-Fortive-to-Buy-boosts-target-to--from-\" target=\"_blank\">Citi raises FTV to Buy</a> from Neutral  with an $84 price target, up from $76, saying the \"industrial cycle\" is in the midst  of a mild downturn that could stabilize while  certain longer-cycle markets remain healthy having largely bypassed the  downturn.</li><li>In recommending FTV, Citi's Andrew Kaplowitz believes stock selectivity is key  and prefers companies with a \"combination of self-help runway and  exposure to resilient long-cycle and/or 'secular' growth end markets.\"</li><li>Credit Suisse analyst John Walsh <a href=\"https://thefly.com/thestreet/realmoney/index.php/FTVid3003952/FTV-Fortive-upgraded-to-Outperform-at-Credit-Suisse-price-target-raised-to-\" target=\"_blank\">upgrades</a> shares to Outperform from  Neutral with an $82 price target, up from $75, saying recent earnings pressure at FTV has been driven by cyclical pressures which reverse in H2 2020.</li><li>FTV's average <a href=\"https://seekingalpha.com/symbol/FTV/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/FTV/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> are both Neutral, while its <a href=\"https://seekingalpha.com/symbol/FTV/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524910\" data-linked=\"Fortive grabs upgrades at Citi, Credit Suisse\" data-tweet=\"$FTV - Fortive grabs upgrades at Citi, Credit Suisse https://seekingalpha.com/news/3524910-fortive-grabs-upgrades-citi-credit-suisse?source=tweet\" data-url=\"https://seekingalpha.com/news/3524910-fortive-grabs-upgrades-citi-credit-suisse\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524875\" data-ts=\"1575914826\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APTO\" target=\"_blank\">APTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524875-aptose-up-38-on-encouraging-cgminus-806-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aptose up 38% on encouraging CG-806 data</a></h4><ul><li>Thinly traded micro cap Aptose Biosciences (<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a> <font color=\"green\">+37.5%</font>) is up on a 27x surge in volume in reaction to <a href=\"https://seekingalpha.com/pr/17722268-aptose-presents-new-preclinical-cgminus-806-data-2019-ash-annual-meeting\" target=\"_blank\">preclinical data</a> on pipeline candidate CG-806. The results were presented at ASH in Orlando.</li><li>In CLL cells, CG-806 inhibited B-cell receptor signaling that led to CLL cell death and reduced proliferation with a greater effect than AbbVie's Imbruvica (ibrutinib).</li><li>In mantle cell lymphoma cells, CG-806 showed superior anti-cancer action versus ibrutinib.</li><li>The company says CG-806 is an oral small molecule FLT3/BTK multi-cluster kinase inhibitor in development for blood cancers. It <a href=\"https://seekingalpha.com/news/3363862-aptose-secures-rights-to-blood-cancer-candidate-in-china-from-crystalgenomics-for-up-to-125m\" target=\"_blank\">in-licensed</a> the asset from South Korea's CrystalGenomics in June 2018.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524875\" data-linked=\"Aptose up 38% on encouraging CG-806 data\" data-tweet=\"$APTO - Aptose up 38% on encouraging CG-806 data https://seekingalpha.com/news/3524875-aptose-up-38-on-encouraging-cgminus-806-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3524875-aptose-up-38-on-encouraging-cgminus-806-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524872\" data-ts=\"1575914578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524872-industrial-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Industrial - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"green\">+23%</font>. Air Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/AIRI' title='Air Industries Group'>AIRI</a>) <font color=\"green\">+9%</font>. Hovnanian Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>) <font color=\"green\">+8%</font>. Charah Solutions (NYSE:<a href='https://seekingalpha.com/symbol/CHRA' title='Charah Solutions, Inc.'>CHRA</a>) <font color=\"green\">+7%</font>. The LGL Group (NYSEMKT:<a href='https://seekingalpha.com/symbol/LGL' title='The LGL Group, Inc.'>LGL</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>U.S. Well Services (NASDAQ:<a href='https://seekingalpha.com/symbol/USWS' title='U.S. Well Services, Inc.'>USWS</a>) <font color=\"red\">-14%</font>. Culp (NYSE:<a href='https://seekingalpha.com/symbol/CULP' title='Culp, Inc.'>CULP</a>) <font color=\"red\">-6%</font>. Babcock &amp; Wilcox (NYSE:<a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a>) <font color=\"red\">-6%</font>. Plug Power (NASDAQ:<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power Inc.'>PLUG</a>) <font color=\"red\">-6%</font>. Forterra (NASDAQ:<a href='https://seekingalpha.com/symbol/FRTA' title='Forterra, Inc.'>FRTA</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524872\" data-linked=\"Industrial - Top 5 Gainers / Losers\" data-tweet=\"$HEBT $AIRI $HOV - Industrial - Top 5 Gainers / Losers https://seekingalpha.com/news/3524872-industrial-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524872-industrial-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524869\" data-ts=\"1575913842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524869-ringcentral-up-bofa-boosts-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RingCentral up as BofA boosts target</a></h4><ul>   <li>RingCentral (NYSE:<a href='https://seekingalpha.com/symbol/RNG' title='RingCentral, Inc.'>RNG</a>) is <font color=\"green\">up 0.6%</font> against a slightly down market after seeing a price target hike from BofA.</li>    <li>The bank raised its target to $198 from $187, now implying 18% upside, and reiterated its Buy rating and \"top pick\" designation.</li>    <li>That's due to a partnership with Avaya (<a href=\"http://seekingalpha.com/symbol/AVYA\" target=\"_blank\">AVYA</a> <font color=\"red\">-2.3%</font>), where BofA's Nikolay Beliov has \"better visibility into the meaningful long-term economic value creation\" after talking with Avaya distributors. That team-up could bring up to 50M users over the long term, Beliov says.</li>    <li>Sell-side analysts are <a href=\"https://seekingalpha.com/symbol/AVYA/ratings/sell-side-ratings\" target=\"_blank\">Bullish overall on RNG</a>, as are <a href=\"https://seekingalpha.com/symbol/AVYA/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors</a>; it has a <a href=\"https://seekingalpha.com/symbol/AVYA/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524869\" data-linked=\"RingCentral up as BofA boosts target\" data-tweet=\"$RNG $AVYA - RingCentral up as BofA boosts target https://seekingalpha.com/news/3524869-ringcentral-up-bofa-boosts-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3524869-ringcentral-up-bofa-boosts-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524867\" data-ts=\"1575913581\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524867-juul-slashes-own-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juul slashes its own valuation</a></h4><ul><li>Altria (<a href='https://seekingalpha.com/symbol/MO' title='Altria Group, Inc.'>MO</a> <font color='green'>+0.5%</font>) is on watch on reports Juul (<a href='https://seekingalpha.com/symbol/JUUL' title='JUUL'>JUUL</a>) lowered the <a href=\"https://www.wsj.com/articles/tiger-global-cuts-juuls-valuation-to-19-billion-11575910758\" target=\"_blank\">valuation</a> on itself to $24B at the end of Q3 from the previous valuation of $38B.</li><li>Juul's CFO referenced changes in market conditions in an internal memo on the valuation cut.</li><li>Separately, Tiger Global Management cut the valuation on its Juul stake by 50% to $19B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524867\" data-linked=\"Juul slashes its own valuation\" data-tweet=\"$MO $JUUL - Juul slashes its own valuation https://seekingalpha.com/news/3524867-juul-slashes-own-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3524867-juul-slashes-own-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>75&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524865\" data-ts=\"1575913354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524865-ar-arql-mbio-and-dplo-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AR, ARQL, MBIO and DPLO among midday movers</a></h4><ul><li><strong>Gainers:</strong> Synthorx (NASDAQ:<a href='https://seekingalpha.com/symbol/THOR' title='Synthorx, Inc.'>THOR</a>) <font color=\"green\">+170%</font>.</li><li>ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) <font color=\"green\">+104%</font>.</li><li>Forty Seven (NASDAQ:<a href='https://seekingalpha.com/symbol/FTSV' title='Forty Seven, Inc.'>FTSV</a>) <font color=\"green\">+89%</font>.</li><li>XBiotech (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIT' title='XBiotech Inc.'>XBIT</a>) <font color=\"green\">+79%</font>.</li><li>Fate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>) <font color=\"green\">+41%</font>.</li><li>Neoleukin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLTX' title='Neoleukin Therapeutics, Inc.'>NLTX</a>) <font color=\"green\">+39%</font>.</li><li>Aptose Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) <font color=\"green\">+29%</font>.</li><li>LMP Automotive (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"green\">+27%</font>.</li><li>Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <font color=\"green\">+24%</font>.</li><li>Stage Stores (NYSE:<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a>) <font color=\"green\">+24%</font>.</li><li><strong>Losers: </strong>Precision BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/DTIL' title='Precision BioSciences, Inc.'>DTIL</a>) <font color=\"red\">-48%</font>.</li><li>Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy, Inc.'>DPLO</a>) <font color=\"red\">-32%</font>.</li><li>ObsEva (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) <font color=\"red\">-17%</font>.</li><li>Neurotrope (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRP' title='Neurotrope, Inc.'>NTRP</a>) <font color=\"red\">-17%</font>.</li><li>Mustang Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/MBIO' title='Mustang Bio, Inc.'>MBIO</a>) <font color=\"red\">-17%</font>.</li><li>Centogene (NASDAQ:<a href='https://seekingalpha.com/symbol/CNTG' title='Centogene N.V.'>CNTG</a>) <font color=\"red\">-15%</font>.</li><li>U.S. Well Services (NASDAQ:<a href='https://seekingalpha.com/symbol/USWS' title='U.S. Well Services, Inc.'>USWS</a>) <font color=\"red\">-15%</font>.</li><li>IMAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/IMAC' title='IMAC Holdings, Inc.'>IMAC</a>) <font color=\"red\">-14%</font>.</li><li>Kosmos Energy (NYSE:<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy Ltd.'>KOS</a>) <font color=\"red\">-13%</font>.</li><li>Tivity Health (NASDAQ:<a href='https://seekingalpha.com/symbol/TVTY' title='Tivity Health, Inc.'>TVTY</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524865\" data-linked=\"AR, ARQL, MBIO and DPLO among midday movers\" data-tweet=\"$THOR $ARQL $FTSV - AR, ARQL, MBIO and DPLO among midday movers https://seekingalpha.com/news/3524865-ar-arql-mbio-and-dplo-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524865-ar-arql-mbio-and-dplo-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524864\" data-ts=\"1575912907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOW\" target=\"_blank\">DOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524864-dow-kraton-upgraded-to-buy-suntrust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dow, Kraton upgraded to Buy at SunTrust</a></h4><ul><li>Dow Inc. (<a href='https://seekingalpha.com/symbol/DOW' title='Dow Inc.'>DOW</a> <font color=\"red\">-0.1%</font>) and Kraton (<a href='https://seekingalpha.com/symbol/KRA' title='Kraton Corporation'>KRA</a> <font color=\"green\">+4.3%</font>) are both <a href=\"https://thefly.com/thestreet/realmoney/index.php/KRA;DOWid3003914/KRA;DOW-Kraton-Dow-Inc-upgraded-to-Buy-at-SunTrust-\" target=\"_blank\">upgraded to Buy</a> from Hold, with respective price targets of $59 and $31, at SunTrust as part of the firm's broader analysis of the chemicals sector.</li><li>For  KRA, SunTrust's James Sheehan notes the proceeds of the Cariflex sale will  go toward its debt reduction, removing a key overhang on the stock, and he anticipates improvement in KRA's macro environment after  2019 headwinds around adverse U.S. weather, inventory destocking and  global demand weakness.</li><li>For DOW, Sheehan cites the low margin  level in the company's chemicals value chains limiting the downside, with added potential earnings contributions coming from its $250M of new  capacity investments.</li><li>DOW's average <a href=\"https://seekingalpha.com/symbol/DOW/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Neutral, while its <a href=\"https://seekingalpha.com/symbol/DOW/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Bullish.</li><li>KRA's average <a href=\"https://seekingalpha.com/symbol/KRA/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Neutral, its <a href=\"https://seekingalpha.com/symbol/KRA/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Bullish, and its <a href=\"https://seekingalpha.com/symbol/KRA/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524864\" data-linked=\"Dow, Kraton upgraded to Buy at SunTrust\" data-tweet=\"$DOW $KRA - Dow, Kraton upgraded to Buy at SunTrust https://seekingalpha.com/news/3524864-dow-kraton-upgraded-to-buy-suntrust?source=tweet\" data-url=\"https://seekingalpha.com/news/3524864-dow-kraton-upgraded-to-buy-suntrust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524858\" data-ts=\"1575912157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTSV\" target=\"_blank\">FTSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524858-forty-seven-up-84-on-positive-data-on-lead-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forty Seven up 84% on positive data on lead candidate</a></h4><ul><li>Thinly traded Forty-Seven (<a href='https://seekingalpha.com/symbol/FTSV' title='Forty Seven, Inc.'>FTSV</a> <font color=\"green\">+83.7%</font>) is up on a healthy 28x surge in volume in response to <a href=\"https://seekingalpha.com/pr/17721624-forty-seven-inc-announces-updated-data-from-ongoing-clinical-trial-of-magrolimab-showing\" target=\"_blank\">updated data</a> from an ongoing <a href=\"https://clinicaltrials.gov/ct2/show/NCT03248479?lead=forty+seven&amp;draw=2&amp;rank=2\" target=\"_blank\">Phase 1b clinical trial</a> evaluating lead candidate magrolimab (5F9), combined with chemo agent azacitidine (Celgene's Vidaza), in treatment-naïve patients with higher-risk myelodysplastic syndromes &#40;MDS&#41; and treatment-naïve AML patients who are ineligible for induction chemo. The results were presented at ASH in Orlando.</li><li>As of the data cutoff on November 18, 62 total participants had been treated, 35 with MDS and 27 with AML.</li><li>In evaluable MDS patients, the overall response rate &#40;ORR&#41; was 92% (n=22/24), including 12 (50%) complete responders. Two patients had stable cancer implying a disease control rate &#40;DCR&#41; of 100% (n=24/24).</li><li>In the AML group, the ORR was 64% (n=14/22), including nine (41%) complete responders. Seven had stable cancer implying a DCR of 95% (n=21/22).</li><li>Median duration of response and overall survival had not been reached.</li><li>No new safety signals were reported.</li><li>The company amended the study protocol to assess dosing every two weeks. Target enrollment of 90 subjects should be completed by Q3 2020.</li><li>Magrolimab is a humanized IgG4 monoclonal antibody that targets an immune checkpoint called CD47 that is overexpressed on cancer cells. Blocking the cell surface protein makes cancer cells susceptible to immune system cells called macrophages. It has Fast Track status in the U.S. for the two disorders.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524858\" data-linked=\"Forty Seven up 84% on positive data on lead candidate\" data-tweet=\"$FTSV - Forty Seven up 84% on positive data on lead candidate https://seekingalpha.com/news/3524858-forty-seven-up-84-on-positive-data-on-lead-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3524858-forty-seven-up-84-on-positive-data-on-lead-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524855\" data-ts=\"1575911106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524855-eastman-kodak-among-consumer-gainers-garrett-motion-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eastman Kodak among consumer gainers; Garrett Motion leads the losers</a></h4><ul><li><b>Gainers: </b>Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+12%</font>. Eastman Kodak (NYSE:<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Company'>KODK</a>) <font color=\"green\">+7%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+7%</font>. Peloton Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/PTON' title='Peloton Interactive, Inc.'>PTON</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Garrett Motion (NYSE:<a href='https://seekingalpha.com/symbol/GTX' title='Garrett Motion Inc.'>GTX</a>) <font color=\"red\">-11%</font>. Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi, Inc.'>FAMI</a>) <font color=\"red\">-8%</font>. MasterCraft Boat (NASDAQ:<a href='https://seekingalpha.com/symbol/MCFT' title='MasterCraft Boat Holdings, Inc.'>MCFT</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524855\" data-linked=\"Eastman Kodak among consumer gainers; Garrett Motion leads the losers\" data-tweet=\"$SOLO $KODK $CAAS - Eastman Kodak among consumer gainers; Garrett Motion leads the losers https://seekingalpha.com/news/3524855-eastman-kodak-among-consumer-gainers-garrett-motion-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524855-eastman-kodak-among-consumer-gainers-garrett-motion-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524848\" data-ts=\"1575909351\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNST\" target=\"_blank\">CNST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524848-constellation-pharma-up-17-on-cpiminus-0610-data-in-mf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Constellation Pharma up 17% on CPI-0610 data in MF</a></h4><ul><li>Constellation Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CNST' title='Constellation Pharmaceuticals, Inc.'>CNST</a> <font color=\"green\">+17.4%</font>) is up on double normal volume on the heels of <a href=\"https://seekingalpha.com/pr/17722185-constellation-pharmaceuticals-provides-updated-preliminary-data-from-manifest-clinical-trial\" target=\"_blank\">updated interim data</a> from an open-label Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02158858?lead=constellation+pharmaceuticals&amp;phase=1&amp;draw=2&amp;rank=4\" target=\"_blank\">MANIFEST</a>, evaluating co-lead candidate CPI-0610, with and without ruxolitinib, in myelofibrosis &#40;MF&#41; patients. The results were presented at ASH in Orlando.</li><li>The primary endpoints are spleen response at week 24 and the rate of red blood transfusion independence and no hemoglobin levels below 8 g/dL.</li><li>In the first-line treatment arm, 80% (n=12/15) of evaluable patients receiving CPI-0610 + ruxolitinib (Incyte's Jakafi) experienced at least a 35% spleen response (SVR35) at week 12. 71% (n=10/14) achieved at least a 50% improvement in Total Symptom Score (TSS50) at week 12.</li><li>In evaluable patients resistant to or intolerant of ruxolitinib who received CPI-061 as add-on treatment, the SVR35 rate was 25% (n=3/12) at week 24, although 94% experienced some degree of spleen volume reduction. The rate of TSS50 at week 24 was 54% (n=7/13). 43% (n=6/14) transitioned from transfusion dependence to independence.</li><li>On the safety front, three JAK-inhibitor-naïve patients receiving the combo regimen experienced serious/life-threatening anemia while one experienced life-threatening thrombocytopenia (low blood platelets) that was reversible. The most common adverse events, mostly mild/moderate, were diarrhea, nausea, dizziness and muscle spasms.</li><li>The company will host an event for investors and analysts today at 12:30 pm ET to discuss the results.</li><li>Shares have been on a tear the past couple of months, up almost nine-fold since touching $6.01 on September 30.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524848\" data-linked=\"Constellation Pharma up 17% on CPI-0610 data in MF\" data-tweet=\"$CNST - Constellation Pharma up 17% on CPI-0610 data in MF https://seekingalpha.com/news/3524848-constellation-pharma-up-17-on-cpiminus-0610-data-in-mf?source=tweet\" data-url=\"https://seekingalpha.com/news/3524848-constellation-pharma-up-17-on-cpiminus-0610-data-in-mf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524849\" data-ts=\"1575909268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MPC\" target=\"_blank\">MPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524849-marathon-petroleum-delek-us-downgraded-j-p-morgan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marathon Petroleum, Delek US downgraded at J.P. Morgan</a></h4><ul><li>Marathon Petroleum (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corporation'>MPC</a> <font color='red'>-1.2%</font>) and Delek US (<a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='red'>-1.3%</font>) are two of today's weakest performers in the energy sector after J.P. Morgan <a href=\"https://thefly.com/thestreet/realmoney/index.php/DK;MPCid3003985/DK;MPC-JPMorgan-downgrades-Delek-US-to-Underweight-Marathon-Petroleum-to-Neutral\" target=\"_blank\">downgrades</a> MPC to Neutral from Overweight with a $67 price target and DK to Underweight from Neutral with a $38 target.</li><li>In his Refining 2020 outlook, JPM analyst Phil Gresh says he believes a fair amount of the IMO 2020 upside potential \"now feels priced  in.\"</li><li>MPC shares now more accurately reflect the value unlocked by the potential from the Speedway spinoff, Gresh says.</li><li>For DK, the near-term degradation in its free cash flow yield from tight inland crude differentials \"make it difficult to get excited about 2020,\" Gresh writes.</li><li>MPC's average <a href=\"https://seekingalpha.com/symbol/MPC/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/MPC/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> are Bullish, and its <a href=\"https://seekingalpha.com/symbol/MPC/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Very Bullish.</li><li>DK's average <a href=\"https://seekingalpha.com/symbol/DK/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, while both its <a href=\"https://seekingalpha.com/symbol/DK/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/DK/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524849\" data-linked=\"Marathon Petroleum, Delek US downgraded at J.P. Morgan\" data-tweet=\"$MPC $DK - Marathon Petroleum, Delek US downgraded at J.P. Morgan https://seekingalpha.com/news/3524849-marathon-petroleum-delek-us-downgraded-j-p-morgan?source=tweet\" data-url=\"https://seekingalpha.com/news/3524849-marathon-petroleum-delek-us-downgraded-j-p-morgan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524824\" data-ts=\"1575907349\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524824-arqule-and-xbiotech-among-healthcare-gainers-precision-biosciences-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ArQule and XBiotech among healthcare gainers; Precision BioSciences leads the losers</a></h4><ul><li><b>Gainers: </b>Synthorx (NASDAQ:<a href='https://seekingalpha.com/symbol/THOR' title='Synthorx, Inc.'>THOR</a>) <font color=\"green\">+170%</font>. ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) <font color=\"green\">+103%</font>. XBiotech (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIT' title='XBiotech Inc.'>XBIT</a>) <font color=\"green\">+80%</font>. Forty Seven (NASDAQ:<a href='https://seekingalpha.com/symbol/FTSV' title='Forty Seven, Inc.'>FTSV</a>) <font color=\"green\">+74%</font>. Aptose Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) <font color=\"green\">+41%</font>.</li><li><b>Losers: </b>Precision BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/DTIL' title='Precision BioSciences, Inc.'>DTIL</a>) <font color=\"red\">-42%</font>. Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy, Inc.'>DPLO</a>) <font color=\"red\">-32%</font>. ObsEva (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) <font color=\"red\">-14%</font>. IMAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/IMAC' title='IMAC Holdings, Inc.'>IMAC</a>) <font color=\"red\">-12%</font>. Neurotrope (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRP' title='Neurotrope, Inc.'>NTRP</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524824\" data-linked=\"ArQule and XBiotech among healthcare gainers; Precision BioSciences leads the losers\" data-tweet=\"$THOR $ARQL $XBIT - ArQule and XBiotech among healthcare gainers; Precision BioSciences leads the losers https://seekingalpha.com/news/3524824-arqule-and-xbiotech-among-healthcare-gainers-precision-biosciences-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524824-arqule-and-xbiotech-among-healthcare-gainers-precision-biosciences-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524815\" data-ts=\"1575906520\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QRVO\" target=\"_blank\">QRVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524815-qorvoplus-3_2-bofa-boosts-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qorvo +3.2% as BofA boosts to Buy</a></h4><ul>   <li>Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc.'>QRVO</a>) is <font color=\"green\">up 3.2%</font> after getting its own two-notch upgrade from BofA, to Buy from Underperform.</li>    <li>Analyst Vivek Arya raised the firm's price target to $130 from $80, now implying 18% upside.</li>    <li>Sentiment is strong, with sell-side analysts <a href=\"https://seekingalpha.com/symbol/QRVO/ratings/sell-side-ratings\" target=\"_blank\">Bullish on average</a> and <a href=\"https://seekingalpha.com/symbol/QRVO/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors Bullish as well</a>. Qorvo has a <a href=\"https://seekingalpha.com/symbol/QRVO/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Very Bullish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524815\" data-linked=\"Qorvo +3.2% as BofA boosts to Buy\" data-tweet=\"$QRVO - Qorvo +3.2% as BofA boosts to Buy https://seekingalpha.com/news/3524815-qorvoplus-3_2-bofa-boosts-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3524815-qorvoplus-3_2-bofa-boosts-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524812\" data-ts=\"1575906170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RVLV\" target=\"_blank\">RVLV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524812-revolve-group-higher-after-morgan-stanley-calls-out-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revolve Group higher after Morgan Stanley calls out upside</a></h4><ul> <li>Revolve Group (<a href='https://seekingalpha.com/symbol/RVLV' title='Revolve Group, Inc.'>RVLV</a> <font color='green'>+2.6%</font>) gains after Morgan Stanley joins the bull camp on the e-commerce fashion retailer.</li> <li>The firm begins coverage on Revolve Group with an Overweight rating and price target of $27 (+50% upside potential).</li> <li><a href=\"https://seekingalpha.com/symbol/RVLV/ratings/sell-side-ratings\" target=\"_blank\">Analyst ratings scorecard</a> on RVLV: 8 Buy-equivalent ratings, 2 Hold-equivalent ratings, 0 Sell-equivalent ratings.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524812\" data-linked=\"Revolve Group higher after Morgan Stanley calls out upside\" data-tweet=\"$RVLV - Revolve Group higher after Morgan Stanley calls out upside https://seekingalpha.com/news/3524812-revolve-group-higher-after-morgan-stanley-calls-out-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3524812-revolve-group-higher-after-morgan-stanley-calls-out-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524806\" data-ts=\"1575904849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPCE\" target=\"_blank\">SPCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524806-virgin-galacticplus-13-after-morgan-stanley-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Virgin Galactic +13% after Morgan Stanley call</a></h4><ul> <li>Virgin Galactic (NYSE:<a href='https://seekingalpha.com/symbol/SPCE' title='Virgin Galactic Holdings, Inc.'>SPCE</a>) rallies after Morgan Stanley's bullish thesis on the space stock circulates investor sentiment.</li> <li>Morgan Stanley analyst Adam Jonas has an interesting sum-of-the-parts analysis on Virgin Galactic.</li><li>\"We believe the addressable market for space tourism, while niche, is supported by a range of industries (e.g., yacht charters and luxury cars). While some investors have described high-speed hypersonic P2P air travel opportunity as 'the icing on the cake', we see Hypersonic as both the cake and the icing, with Space Tourism as the oven. We value the space tourism business at no more than $10/share,\" writes Jonas.</li> <li>\"The third phase of the VG business model involves hypersonic P2P travel, where we forecast ~$800bn in annual sales by 2040. For VG, the billions in investment and decades of work associated with building vehicles and launching spaceships should position it favorably,\" he adds.</li><li>The Morgan Stanley price target of $22 price target consists of the $10 per share for the space tourism business and $12 per share for the Hypersonic opportunity.</li> <li>The bull case valuation on Virgin Galactic is $60 reflecting \"full valuation\" of Phase 3 and the bear case scenario leads to a price target of $1 off safety or market acceptance issues.</li> <li>Shares of Virgin Galactic are <font color=\"green\">up 12.95%</font> to $8.40 on volume of over 2.65M vs. the daily average of 2.47M shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524710-rocket-ride-for-virgin-galactic-after-morgan-stanley-initiation\" target=\"_blank\">Rocket ride for Virgin Galactic after Morgan Stanley initiation</a> (Dec. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3524806\" data-linked=\"Virgin Galactic +13% after Morgan Stanley call\" data-tweet=\"$SPCE - Virgin Galactic +13% after Morgan Stanley call https://seekingalpha.com/news/3524806-virgin-galacticplus-13-after-morgan-stanley-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3524806-virgin-galacticplus-13-after-morgan-stanley-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524800\" data-ts=\"1575904567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNCL\" target=\"_blank\">MNCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524800-monocle-acquisition-and-aersale-announce-business-combination\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monocle Acquisition and AerSale announce business combination</a></h4><ul><li>Monocle Acquisition (<a href='https://seekingalpha.com/symbol/MNCL' title='Monocle Acquisition Corporation'>MNCL</a> <font color=\"green\">+1.6%</font>) and AerSale have entered into a definitive agreement to merge in a transaction with an implied enterprise value of ~$430M, equating to ~6.3x AerSale's forecasted 2020 Adj. EBITDA.</li><li>The combined company, which will be named AerSale Corporation, will be publicly traded on the Nasdaq Stock Market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524800\" data-linked=\"Monocle Acquisition and AerSale announce business combination\" data-tweet=\"$MNCL - Monocle Acquisition and AerSale announce business combination https://seekingalpha.com/news/3524800-monocle-acquisition-and-aersale-announce-business-combination?source=tweet\" data-url=\"https://seekingalpha.com/news/3524800-monocle-acquisition-and-aersale-announce-business-combination\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524788\" data-ts=\"1575904391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524788-pg-and-e-jumps-to-two-month-high-on-13_5b-settlement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E jumps to two-month high on $13.5B settlement</a></h4><ul><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='green'>+16.7%</font>) <a href=\"https://finance.yahoo.com/news/pg-e-reaches-13-5-040705905.html\" target=\"_blank\">surges in early trading</a> following <a href=\"https://seekingalpha.com/news/3524621-pg-and-e-announces-13_5b-settlement-in-california-wildfires\" target=\"_blank\">Friday's announcement</a> that it reached a $13.5B settlement with victims of 2017 and 2018 wildfires ignited by its power lines, a major step toward resolving its bankruptcy case.</li><li>The utility said it also received more than $12B in equity backstop commitments to support the <a href=\"https://www.sec.gov/Archives/edgar/data/75488/000095015719001393/ex10-1.htm\" target=\"_blank\">settlement</a> and its plan of reorganization.</li><li>PG&amp;E discloses it will <a href=\"https://www.reuters.com/article/us-california-wildfire-pg-e-us/bankrupt-pge-to-take-4-9-billion-more-charge-on-wildfire-victim-claims-idUSKBN1YD1IB?il=0\" target=\"_blank\">take a related $4.9B pre-tax charge</a> in the current quarter; it previously took a $2.5B charge in Q3 for estimated third-party claims related to 2017 wildfires and 2018 Camp fire.</li><li>The deal reportedly could force the group of bondholders, led by Elliott Management and Pacific Investment Management, who want to take over the company to <a href=\"https://www.wsj.com/articles/pg-e-fire-victim-settlement-threatens-elliott-plan-11575775107\" target=\"_blank\">re-evaluate their legal strategy</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524788\" data-linked=\"PG&amp;E jumps to two-month high on $13.5B settlement\" data-tweet=\"$PCG - PG&amp;E jumps to two-month high on $13.5B settlement https://seekingalpha.com/news/3524788-pg-and-e-jumps-to-two-month-high-on-13_5b-settlement?source=tweet\" data-url=\"https://seekingalpha.com/news/3524788-pg-and-e-jumps-to-two-month-high-on-13_5b-settlement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524781\" data-ts=\"1575904126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VGR\" target=\"_blank\">VGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524781-vector-group-dips-after-key-shareholder-lightens-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vector Group dips after key shareholder lightens up</a></h4><ul> <li>Vector Group (<a href='https://seekingalpha.com/symbol/VGR' title='Vector Group Ltd.'>VGR</a> <font color=\"red\">-1.2%</font>) trades slightly lower after stakeholder Phillip Frost discloses the sale of 5.75M shares.</li> <li>Frost still holds ~14.75M shares following the transaction through the Frost Gamma Investments Trust. Frost once held more than 15% of total shares.</li> <li><a href=\"https://seekingalpha.com/symbol/VGR/sec-filings\" target=\"_blank\">SEC Form 4</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3524781\" data-linked=\"Vector Group dips after key shareholder lightens up\" data-tweet=\"$VGR - Vector Group dips after key shareholder lightens up https://seekingalpha.com/news/3524781-vector-group-dips-after-key-shareholder-lightens-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3524781-vector-group-dips-after-key-shareholder-lightens-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524778\" data-ts=\"1575903502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524778-biocept-prices-equity-offering-shares-down-52\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept prices equity offering, shares down 52%</a></h4><ul><li>Nano cap Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color=\"red\">-51.6%</font>) slumps on a 26x surge in volume in reaction to its <a href=\"https://seekingalpha.com/pr/17722094-biocept-announces-pricing-of-10_0-million-underwritten-public-offering\" target=\"_blank\">public offering</a> of 24.6M common shares (or pre-funded warrants) and five-year warrants to purchase up to the same number of shares at $0.45 per share and accompanying warrant.</li><li>Gross proceeds should be ~$10M. Closing date is December 11.</li><li>Friday's close was $0.54.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524778\" data-linked=\"Biocept prices equity offering, shares down 52%\" data-tweet=\"$BIOC - Biocept prices equity offering, shares down 52% https://seekingalpha.com/news/3524778-biocept-prices-equity-offering-shares-down-52?source=tweet\" data-url=\"https://seekingalpha.com/news/3524778-biocept-prices-equity-offering-shares-down-52\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524770\" data-ts=\"1575902953\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524770-abeo-on-go-late-stage-study-of-rdeb-gene-therapy-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abeo on go with late-stage study of RDEB gene therapy; shares up 3%</a></h4><ul><li>Abeona Therapeutics (<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a> <font color=\"green\">+2.7%</font>) is up out of the gate this morning in response to the <a href=\"https://seekingalpha.com/pr/17721931-abeona-therapeutics-cleared-to-initiate-pivotal-phase-3-clinical-trial-evaluating-ebminus-101\" target=\"_blank\">FDA's sign-off</a> on a Phase 3 clinical trial, VIITAL, evaluating gene therapy EB-101 in patients with a rare inherited skin-blistering disorder called recessive dystrophic epidermolysis bullosa &#40;RDEB&#41;.</li><li>The company is on go to start the late-stage study after the agency removed the clinical hold on the program subsequent to the submission of additional transport stability data on EB-101 to clinical sites.</li><li>VIITAL's primary endpoint will be the proportion of wounds showing at least 50% healing at month 3 compared to untreated wounds on the same patient.</li><li>EB-101 has Breakthrough Therapy, Orphan Drug, Rare Pediatric designation and Regenerative Medicine Advanced Therapy status for the indication.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524770\" data-linked=\"Abeo on go with late-stage study of RDEB gene therapy; shares up 3%\" data-tweet=\"$ABEO - Abeo on go with late-stage study of RDEB gene therapy; shares up 3% https://seekingalpha.com/news/3524770-abeo-on-go-late-stage-study-of-rdeb-gene-therapy-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3524770-abeo-on-go-late-stage-study-of-rdeb-gene-therapy-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524763\" data-ts=\"1575901817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTON\" target=\"_blank\">PTON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524763-baird-confident-on-peloton\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird confident on Peloton</a></h4><ul> <li>Baird digs into the cutoff times posted on Peloton's (NASDAQ:<a href='https://seekingalpha.com/symbol/PTON' title='Peloton Interactive, Inc.'>PTON</a>) website to surmise that the demand is strong for the holiday period.</li> <li>The firm keeps its Outperform rating on Peloton and price target of $35 on its view that the advertising controversy won't impact sales this quarter or beyond.</li> <li>Shares of PTON are <font color=\"green\">up 1.44%</font> in premarket trading to $33.09.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524033-rage-against-peloton-machine\" target=\"_blank\">Rage against the Peloton machine</a> (Dec. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524763\" data-linked=\"Baird confident on Peloton\" data-tweet=\"$PTON - Baird confident on Peloton https://seekingalpha.com/news/3524763-baird-confident-on-peloton?source=tweet\" data-url=\"https://seekingalpha.com/news/3524763-baird-confident-on-peloton\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524760\" data-ts=\"1575901378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWKS\" target=\"_blank\">SWKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524760-skyworksplus-2_4-amid-two-notch-upgrade-from-bofa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Skyworks +2.4% amid two-notch upgrade from BofA</a></h4><ul>   <li>Skyworks Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>) is <font color=\"green\">up 2.4%</font> premarket after a two-notch upgrade from BofA Merrill Lynch, to Buy from Underperform.</li>    <li>The bank's raised its price target to $122 from $92, implying 20% upside.</li>    <li>Sell-side analysts are <a href=\"https://seekingalpha.com/symbol/SWKS/ratings/sell-side-ratings\" target=\"_blank\">Bullish on Skyworks on average</a>, while <a href=\"https://seekingalpha.com/symbol/SWKS/ratings/author-ratings\" target=\"_blank\">Seeking Alpha authors are Neutral</a>; the stock has a <a href=\"https://seekingalpha.com/symbol/SWKS/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524760\" data-linked=\"Skyworks +2.4% amid two-notch upgrade from BofA\" data-tweet=\"$SWKS - Skyworks +2.4% amid two-notch upgrade from BofA https://seekingalpha.com/news/3524760-skyworksplus-2_4-amid-two-notch-upgrade-from-bofa?source=tweet\" data-url=\"https://seekingalpha.com/news/3524760-skyworksplus-2_4-amid-two-notch-upgrade-from-bofa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524759\" data-ts=\"1575901295\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524759-blue-pcg-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BLUE, PCG among premarket gainers</a></h4><ul><li>Synthorx (NASDAQ:<a href='https://seekingalpha.com/symbol/THOR' title='Synthorx, Inc.'>THOR</a>) <font color=\"green\">+169%</font> on being <a href=\"https://seekingalpha.com/news/3524647-sanofi-to-buy-synthorx-for-2_5b\" target=\"_blank\">acquired</a> by Sanofi.</li><li>XBiotech (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIT' title='XBiotech Inc.'>XBIT</a>) <font color=\"green\">+115%</font> on <a href=\"https://seekingalpha.com/news/3524623-xbiotech-out-licenses-anti-inflammatory-antibody-to-janssen-for-up-to-1_35b\" target=\"_blank\">agreement </a>with Johnson &amp; Johnson unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab.</li><li>ArQule (NASDAQ:<a href='https://seekingalpha.com/symbol/ARQL' title='ArQule, Inc.'>ARQL</a>) <font color=\"green\">+103%</font> on <a href=\"https://seekingalpha.com/news/3524680-arqule-up-101-premarket-on-merck-bid\" target=\"_blank\">Merck bid</a>.</li><li>Fate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>) <font color=\"green\">+34%</font> on <a href=\"https://seekingalpha.com/news/3524743-positive-data-on-fate-therapeutics-nk-cell-candidates-stoke-shares-up-35-premarket\" target=\"_blank\">positive data</a> on Fate Therapeutics' NK cell candidates stoke shares.</li><li>Aptose Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APTO' title='Aptose Biosciences Inc.'>APTO</a>) <font color=\"green\">+19%</font> on <a href=\"https://seekingalpha.com/pr/17721347-aptose-presents-highlights-from-corporate-event-ash\" target=\"_blank\">highlights</a> from corporate event at ASH.</li><li>PDL BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/pr/17721709-pdl-biopharma-announces-completion-of-strategic-review-process\" target=\"_blank\">completion</a> of strategic review process.</li><li>Support.com (NASDAQ:<a href='https://seekingalpha.com/symbol/SPRT' title='Support.com, Inc.'>SPRT</a>) <font color=\"green\">+18%</font>.</li><li>PG&amp;E (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) <font color=\"green\">+16%</font> on <a href=\"https://seekingalpha.com/news/3524621-pg-and-e-announces-13_5b-settlement-in-california-wildfires\" target=\"_blank\">announcing</a> $13.5B settlement in California wildfires.</li><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) <font color=\"green\">+16%</font> on <a href=\"https://seekingalpha.com/news/3524712-tg-therapeutics-up-24-premarket-on-positive-data-on-triple-combo-in-leukemia\" target=\"_blank\">positive data</a> on triple combo in leukemia.</li><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) <font color=\"green\">+17%</font> on <a href=\"https://seekingalpha.com/pr/17721931-abeona-therapeutics-cleared-to-initiate-pivotal-phase-3-clinical-trial-evaluating-ebminus-101\" target=\"_blank\">initiating</a> pivotal phase 3 clinical trial evaluating EB-101 gene therapy for recessive dystrophic epidermolysis bullosa.</li><li>ObsEva SA (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/news/3524726-obseva-up-26-premarket-on-positive-linzagolix-data\" target=\"_blank\">positive</a> linzagolix data.</li><li>LMP Automotive Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"green\">+13%</font>.</li><li>Agios Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a>) <font color=\"green\">+14%</font> on <a href=\"https://seekingalpha.com/news/3524751-agios-up-13-premarket-positive-tibsovo-data\" target=\"_blank\">positive</a> Tibsovo data.</li><li>Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3524719-antero-resources-unveils-midstream-fee-reductions-asset-sale-program\" target=\"_blank\">midstream fee reductions</a>, asset sale program.</li><li>LG Display (NYSE:<a href='https://seekingalpha.com/symbol/LPL' title='LG Display Co., Ltd.'>LPL</a>) <font color=\"green\">+8%</font>.</li><li>Virgin Galactic Holdings (NYSE:<a href='https://seekingalpha.com/symbol/SPCE' title='Virgin Galactic Holdings, Inc.'>SPCE</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3524710-rocket-ride-for-virgin-galactic-after-morgan-stanley-initiation\" target=\"_blank\">Morgan Stanley initiation</a>.</li><li>Antero Midstream (NYSE:<a href='https://seekingalpha.com/symbol/AM' title='Antero Midstream Corporation'>AM</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3524719-antero-resources-unveils-midstream-fee-reductions-asset-sale-program\" target=\"_blank\">midstream fee reductions</a>, asset sale program.</li><li>Matinas BioPharma Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/MTNB' title='Matinas BioPharma Holdings, Inc.'>MTNB</a>) <font color=\"green\">+5%</font>.</li><li>Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) <font color=\"green\">+6%</font>.</li><li>bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524759\" data-linked=\"BLUE, PCG among premarket gainers\" data-tweet=\"$THOR $XBIT $ARQL - BLUE, PCG among premarket gainers https://seekingalpha.com/news/3524759-blue-pcg-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524759-blue-pcg-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524758\" data-ts=\"1575901051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETNB\" target=\"_blank\">ETNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524758-wells-bullish-on-fate-therapeutics-after-ash-presentations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells bullish on Fate Therapeutics after ASH presentations</a></h4><ul><li>89bio (NASDAQ:<a href='https://seekingalpha.com/symbol/ETNB' title='89bio, Inc.'>ETNB</a>) initiated with Neutral rating and $33 (15% upside) price target at BofA Merrill Lynch, Outperform with a $60 target of Oppenheimer and Outperform with a $36 target at RBC.</li><li>Zymeworks (NYSE:<a href='https://seekingalpha.com/symbol/ZYME' title='Zymeworks Inc.'>ZYME</a>) initiated with Neutral rating and $43 (3% upside) price target at JPMorgan.</li><li>Fate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>) upgraded to Overweight with a $24 (76% upside) price target at Well Fargo. Shares up 31% premarket on <a href=\"https://seekingalpha.com/news/3524743-positive-data-on-fate-therapeutics-nk-cell-candidates-stoke-shares-up-35-premarket\" target=\"_blank\">positive data</a> presented as ASH in Orlando.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524758\" data-linked=\"Wells bullish on Fate Therapeutics after ASH presentations\" data-tweet=\"$ETNB $ZYME $FATE - Wells bullish on Fate Therapeutics after ASH presentations https://seekingalpha.com/news/3524758-wells-bullish-on-fate-therapeutics-after-ash-presentations?source=tweet\" data-url=\"https://seekingalpha.com/news/3524758-wells-bullish-on-fate-therapeutics-after-ash-presentations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524757\" data-ts=\"1575901047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524757-wingstopplus-3-after-goldman-ratchets-up-conviction\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wingstop +3% after Goldman ratchets up the conviction</a></h4><ul> <li>Shares of Wingstop (NASDAQ:<a href='https://seekingalpha.com/symbol/WING' title='Wingstop Inc.'>WING</a>) move higher after being added to the Conviction Buy List at Goldman Sachs.</li> <li>Goldman already had a Buy rating and price target of $140 on the restaurant stock, but is expressing even more confidence into Wingstop's highly-anticipated Analyst Day event on January 16.</li> <li>WING <font color=\"green\">+3.03%</font> premarket to $82.70 vs. a 52-week trading range of $56.95 to $107.43.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524757\" data-linked=\"Wingstop +3% after Goldman ratchets up the conviction\" data-tweet=\"$WING - Wingstop +3% after Goldman ratchets up the conviction https://seekingalpha.com/news/3524757-wingstopplus-3-after-goldman-ratchets-up-conviction?source=tweet\" data-url=\"https://seekingalpha.com/news/3524757-wingstopplus-3-after-goldman-ratchets-up-conviction\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524753\" data-ts=\"1575900747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REPL\" target=\"_blank\">REPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524753-replimune-appoints-jean-m-franchi-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Replimune appoints Jean M. Franchi as CFO</a></h4><ul><li>Replimune Group (<a href='https://seekingalpha.com/symbol/REPL' title='Replimune Group, Inc.'>REPL</a> <font color='green'>+3%</font>) <a href=\"https://seekingalpha.com/pr/17721778-replimune-strengthens-executive-team-appointment-of-jean-franchi-chief-financial-officer\" target=\"_blank\">appoints</a> Jean M. Franchi as Chief Financial Officer.</li><li>Ms. Franchi brings to Replimune over 30 years of experience in the biotechnology and life sciences industry of varying sizes and stages in both the U.S. and international markets.</li><li>Most recently, Ms. Franchi served as the Chief Financial Officer for Merrimack Pharmaceuticals.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524753\" data-linked=\"Replimune appoints Jean M. Franchi as CFO\" data-tweet=\"$REPL - Replimune appoints Jean M. Franchi as CFO https://seekingalpha.com/news/3524753-replimune-appoints-jean-m-franchi-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3524753-replimune-appoints-jean-m-franchi-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524751\" data-ts=\"1575900547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGIO\" target=\"_blank\">AGIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524751-agios-up-13-premarket-positive-tibsovo-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agios up 13% premarket positive Tibsovo data</a></h4><ul><li>Agios Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/AGIO' title='Agios Pharmaceuticals, Inc.'>AGIO</a>) is up <font color=\"green\">13%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17721775-agios-presents-translational-data-to-characterize-role-of-tibsovo-ivosidenib-treatment-in\" target=\"_blank\">data</a> on the combination of Tibsovo (ivosidenib) and chemo agent azacitidine (Celgene's Vidaza) in IDH1 mutation-positive AML patients. The results were presented at ASH in Orlando.</li><li>Results from 23 newly diagnosed participants in a Phase 1/2 study showed a 61% (n=14) complete response &#40;CR&#41; rate, increasing to 70% (n=16) if CRs with partial hematologic recovery were included. Median duration of CR had not been reached at data cutoff.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524751\" data-linked=\"Agios up 13% premarket positive Tibsovo data\" data-tweet=\"$AGIO - Agios up 13% premarket positive Tibsovo data https://seekingalpha.com/news/3524751-agios-up-13-premarket-positive-tibsovo-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3524751-agios-up-13-premarket-positive-tibsovo-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524750\" data-ts=\"1575900501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524750-healthcare-stocks-among-major-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare stocks among major premarket losers</a></h4><ul><li>Diplomat Pharmacy (NYSE:<a href='https://seekingalpha.com/symbol/DPLO' title='Diplomat Pharmacy, Inc.'>DPLO</a>) <font color=\"red\">-32%</font> on <a href=\"https://seekingalpha.com/news/3524676-diplomat-down-31-premarket-on-discounted-unh-bid\" target=\"_blank\">discounted</a> UNH bid.</li><li>KalVista Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceuticals, Inc.'>KALV</a>) <font color=\"red\">-18%</font> after KVD001 <a href=\"https://seekingalpha.com/news/3524730-kalvistas-kvd001-flunks-mid-stage-dme-study-shares-down-20-premarket\" target=\"_blank\">flunks</a> mid-stage DME study.</li><li>Taronis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TRNX' title='Taronis Technologies, Inc.'>TRNX</a>) <font color=\"red\">-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524750\" data-linked=\"Healthcare stocks among major premarket losers\" data-tweet=\"$DPLO $KALV $TRNX - Healthcare stocks among major premarket losers https://seekingalpha.com/news/3524750-healthcare-stocks-among-major-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3524750-healthcare-stocks-among-major-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524743\" data-ts=\"1575899625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FATE\" target=\"_blank\">FATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524743-positive-data-on-fate-therapeutics-nk-cell-candidates-stoke-shares-up-35-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Positive data on Fate Therapeutics&#39; NK cell candidates stoke shares, up 35% premarket</a></h4><ul><li>Fate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>) continues its premarket momentum, up <font color=\"green\">35%</font>, on the heels of <a href=\"https://seekingalpha.com/pr/17721330-fate-therapeutics-announces-clinical-data-from-landmark-phase-1-studies-of-first-ever\" target=\"_blank\">additional data</a> on its off-the-shelf natural killer &#40;NK&#41; cell product candidates. The results were presented at ASH in Orlando.</li><li>Phase 1 data on FT500, what the company says is the first-ever cell therapy derived from a clonal master induced pluripotent stem line (no patient matching required) to enter the clinic in the U.S., showed anti-leukemic activity and stem cell recovery at day 42 following three once-weekly doses in AML patients. In 12 patients treated thus far, no dose-limiting toxicities or serious/life-threatening FT500-related adverse events, including cytokine release syndrome, have been observed.</li><li>Data from the first AML patient in a Phase 1 evaluating FT516, an off-the-shelf NK cell product candidate engineered to express a high affinity to a receptor called CD16 Fc, alone and in combination with CD20-directed monoclonal antibodies, showed promising action. At day 42 following the first cycle of treatment there was no structural evidence of leukemia and no dose-limiting toxicities.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524743\" data-linked=\"Positive data on Fate Therapeutics&#39; NK cell candidates stoke shares, up 35% premarket\" data-tweet=\"$FATE - Positive data on Fate Therapeutics&#39; NK cell candidates stoke shares, up 35% premarket https://seekingalpha.com/news/3524743-positive-data-on-fate-therapeutics-nk-cell-candidates-stoke-shares-up-35-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3524743-positive-data-on-fate-therapeutics-nk-cell-candidates-stoke-shares-up-35-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524740\" data-ts=\"1575899108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524740-just-eat-mulls-over-new-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Just Eat mulls over new offer</a></h4><ul> <li>Just Eat (<a href='https://seekingalpha.com/symbol/JSTLF' title='Just Eat plc'>OTC:JSTLF</a>, <a href='https://seekingalpha.com/symbol/JSTTY' title='Just Eat plc'>OTCPK:JSTTY</a>) says it's considering the higher cash offer doled out by Prosus earlier today, according to The Times.</li> <li>The company's board has previously backed an offer from Takeaway.com (<a href='https://seekingalpha.com/symbol/TKAYF' title='Takeaway.com N.V.'>OTCPK:TKAYF</a>).</li> <li>Takeaway.com maintains that the new Prosus is \"derisory as a cash exit price.\"</li> <li>Shares of Just Eat are <font color=\"green\">up 0.55%</font> in London trading amid the M&amp;A drama.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3524740\" data-linked=\"Just Eat mulls over new offer\" data-tweet=\"$JSTLF $JSTTY $TKAYF - Just Eat mulls over new offer https://seekingalpha.com/news/3524740-just-eat-mulls-over-new-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3524740-just-eat-mulls-over-new-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524731\" data-ts=\"1575897568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APEI\" target=\"_blank\">APEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524731-american-public-education-adds-buyback-firepower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Public Education adds buyback firepower</a></h4><ul> <li>American Public Education (NASDAQ:<a href='https://seekingalpha.com/symbol/APEI' title='American Public Education, Inc.'>APEI</a>) says its board authorized the company to repurchase another $25M worth of shares.</li> <li>No expiration date for the share repurchase agreement was disclosed.</li> <li>The buyback authorization amount accounts for about 6.5% of all APEI shares at Friday's closing price of $25.12.</li>  <li><a href=\"https://seekingalpha.com/filing/4728483\" target=\"_blank\">SEC Form 8-K</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3524731\" data-linked=\"American Public Education adds buyback firepower\" data-tweet=\"$APEI - American Public Education adds buyback firepower https://seekingalpha.com/news/3524731-american-public-education-adds-buyback-firepower?source=tweet\" data-url=\"https://seekingalpha.com/news/3524731-american-public-education-adds-buyback-firepower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524730\" data-ts=\"1575897409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KALV\" target=\"_blank\">KALV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524730-kalvistas-kvd001-flunks-mid-stage-dme-study-shares-down-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KalVista&#39;s KVD001 flunks mid-stage DME study; shares down 20% premarket</a></h4><ul><li>Thinly traded micro cap KalVista Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KALV' title='KalVista Pharmaceuticals, Inc.'>KALV</a>) slumps <font color=\"red\">20%</font> premarket on average volume in reaction to <a href=\"https://seekingalpha.com/pr/17721592-kalvista-pharmaceuticals-reports-phase-2-clinical-trial-results-in-patients-diabetic-macular\" target=\"_blank\">unsuccessful results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03466099?lead=kalvista&amp;phase=12&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating KVD001 in diabetic macular edema &#40;DME&#41; patients who failed to respond adequately to previous anti-VEGF therapy.</li><li>KVD001, a small molecule plasma kallikrein inhibitor administered via intravitreal injection, failed to sufficiently separate from sham (placebo) as measured by best corrected visual acuity &#40;BCVA&#41; at week 16, the primary endpoint. Specifically, the relative effect of KVD001 on BCVA was +1.5 letters for the 3μg dose (p=0.465) and +2.6 letters (p=0.223) for the 6μg dose, both well short of statistical significance. No statistically valid differences were noted in key secondary endpoints either.</li><li>On a positive note, KVD001 showed protection against vision loss. 32.5% of participants in the treatment group experienced a reduction in vision compared to 54.5% in the sham group (p=0.042).</li><li>Merck (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a>) has an option to acquire the rights to KVD001 under a <a href=\"https://seekingalpha.com/news/3300131-kalvista-pharma-inks-deal-merck-for-dme-candidate-kvd001-shares-up-108-premarket\" target=\"_blank\">2017 agreement</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3524730\" data-linked=\"KalVista&#39;s KVD001 flunks mid-stage DME study; shares down 20% premarket\" data-tweet=\"$KALV $MRK - KalVista&#39;s KVD001 flunks mid-stage DME study; shares down 20% premarket https://seekingalpha.com/news/3524730-kalvistas-kvd001-flunks-mid-stage-dme-study-shares-down-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3524730-kalvistas-kvd001-flunks-mid-stage-dme-study-shares-down-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524726\" data-ts=\"1575897088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OBSV\" target=\"_blank\">OBSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524726-obseva-up-26-premarket-on-positive-linzagolix-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ObsEva up 26% premarket on positive linzagolix data</a></h4><ul> <li>ObsEva SA (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) is up <font color=\"green\">26%</font> premarket on the heels of <a href=\"https://seekingalpha.com/pr/17721425-obseva-announces-positive-results-from-uterine-fibroids-phase-3-study-primrose-2-of\" target=\"_blank\">positive results</a> from a Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/study/NCT03070951?spons=ObsEva&amp;phase=2&amp;draw=2&amp;rank=5\" target=\"_blank\">PRIMROSE 2</a> trial evaluating linzagolix, including 100 mg and 200 mg doses, both with and without hormonal add-back therapy &#40;ABT&#41; for the treatment of heavy menstrual bleeding &#40;HMB&#41; due to uterine fibroids.</li>         <li>The trial enrolled 535 women. The primary efficacy endpoint was the reduction in HMB.</li>  <li>The responder rate was 93.9% for women receiving 200 mg with ABT and 56.7% for women receiving 100 mg without ABT, compared to 29.4% in the placebo group.</li><li>Both doses achieved significant rates of amenorrhea (p &lt; 0.001), reduction in pain (p &lt; 0.001), and improvement in quality of life (p &lt; 0.001).</li><li>Additionally, significant improvement in hemoglobin levels, a reduction in number of days of bleeding and reduction in uterine volume were observed.</li><li>A significant reduction in fibroid volume was also observed for the 200 mg dose with ABT (p &lt; 0.008).</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3524726\" data-linked=\"ObsEva up 26% premarket on positive linzagolix data\" data-tweet=\"$OBSV - ObsEva up 26% premarket on positive linzagolix data https://seekingalpha.com/news/3524726-obseva-up-26-premarket-on-positive-linzagolix-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3524726-obseva-up-26-premarket-on-positive-linzagolix-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524714\" data-ts=\"1575896307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMM\" target=\"_blank\">MMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524714-3m-slips-1-citi-downgrades-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3M slips 1% as Citi downgrades stock</a></h4><ul><li>Citi analyst Andrew Kaplowitz has <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Citi+Downgrades+3M+%28MMM%29+to+Neutral+on+Lingering+Overhang/16221232.html\" target=\"_blank\">lowered</a> 3M (NYSE:<a href='https://seekingalpha.com/symbol/MMM' title='3M Company'>MMM</a>) from Buy to Neutral, while keeping its price target unchanged at $180.</li><li>\"While we think 3M's shorter-cycle end markets could be closer to a bottom and execution seems poised to improve, growing PFAS-litigation related risks could be a lingering overhang that prevents a re-rating to its former premium multiple.\"</li><li>MMM <font color=\"red\">-1.1% </font>premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3524714\" data-linked=\"3M slips 1% as Citi downgrades stock\" data-tweet=\"$MMM - 3M slips 1% as Citi downgrades stock https://seekingalpha.com/news/3524714-3m-slips-1-citi-downgrades-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3524714-3m-slips-1-citi-downgrades-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524712\" data-ts=\"1575895890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524712-tg-therapeutics-up-24-premarket-on-positive-data-on-triple-combo-in-leukemia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics up 24% premarket on positive data on triple combo in leukemia</a></h4><ul><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) is up <font color=\"green\">24%</font> premarket on light volume on the heels of <a href=\"https://seekingalpha.com/pr/17721383-tg-therapeutics-announces-oral-presentation-of-umbralisib-ublituximab-and-venetoclax-triple\" target=\"_blank\">positive results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03379051?lead=tg+therapeutics&amp;phase=0&amp;draw=2&amp;rank=9\" target=\"_blank\">Phase 1/2 clinical tria</a>l evaluating the combination of ublituximab, umbralisib (U2) and venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia &#40;CLL&#41;. The data were presented at ASH in Orlando.</li><li>The overall response rate &#40;ORR&#41; in evaluable patients was 87% (n=20/23) after U2 induction period at cycle 3, prior to treatment with venetoclax, including patients who failed to respond to AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) Imbruvica (ibrutinib). The ORR was 100% (n=13/13) after cycle 7 of the triple combo.</li><li>U2 induction appeared to reduce the risk of <a href=\"https://jamanetwork.com/journals/jamaoncology/fullarticle/2680750\" target=\"_blank\">tumor lysis syndrome</a> (a large number of cancer cells die within a short period, releasing their contents in the blood, depressing calcium levels and affecting the function of certain organs) associated with venetoclax.</li><li>Ublituximab is an anti-CD20 monoclonal antibody. Umbralisib is a dual PI3K delta and CK1 epsilon inhibitor. Venetoclax, marketed as Venclexta by AbbVie and Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a>), is a BCL-2 inhibitor.</li><li>Data from a Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02612311?lead=tg+therapeutics&amp;phase=2&amp;draw=2&amp;rank=4\" target=\"_blank\">UNITY-CLL</a>, comparing U2 to Roche's Gazyva (obinutuzumab) + chemo agent chlorambucil should be available in the coming months.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524712\" data-linked=\"TG Therapeutics up 24% premarket on positive data on triple combo in leukemia\" data-tweet=\"$TGTX $ABBV $RHHBY - TG Therapeutics up 24% premarket on positive data on triple combo in leukemia https://seekingalpha.com/news/3524712-tg-therapeutics-up-24-premarket-on-positive-data-on-triple-combo-in-leukemia?source=tweet\" data-url=\"https://seekingalpha.com/news/3524712-tg-therapeutics-up-24-premarket-on-positive-data-on-triple-combo-in-leukemia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524710\" data-ts=\"1575895571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPCE\" target=\"_blank\">SPCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524710-rocket-ride-for-virgin-galactic-after-morgan-stanley-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rocket ride for Virgin Galactic after Morgan Stanley initiation</a></h4><ul> <li>Morgan Stanley launches new coverage on Virgin Galactic (NYSE:<a href='https://seekingalpha.com/symbol/SPCE' title='Virgin Galactic Holdings, Inc.'>SPCE</a>) with an Overweight rating ahead of a space summit conference the firm is hosting this week.</li> <li>Analyst Adam Jonas and team reiterates prior comments on the upside for Virgin Galactic beyond space tourism, particularly hypersonic P2P air travel.</li> <li>Morgan Stanley's price target of $22 on SPCE factors in $12 for the hypersonic upside.</li> <li>Shares of Virgin Galactic are <font color=\"green\">up 8.40%</font> to $7.87 in premarket trading vs. the post-merger range of $6.90 to $12.93.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524710\" data-linked=\"Rocket ride for Virgin Galactic after Morgan Stanley initiation\" data-tweet=\"$SPCE - Rocket ride for Virgin Galactic after Morgan Stanley initiation https://seekingalpha.com/news/3524710-rocket-ride-for-virgin-galactic-after-morgan-stanley-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3524710-rocket-ride-for-virgin-galactic-after-morgan-stanley-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524705\" data-ts=\"1575895233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THO\" target=\"_blank\">THO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524705-thor-industriesplus-2-after-posting-margin-improvement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Thor Industries +2% after posting margin improvement</a></h4><ul> <li>Thor Industries (NYSE:<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a>) reports <a href=\"https://seekingalpha.com/pr/17721575-thor-announces-net-sales-up-22_9-and-gross-margins-improve-250-basis-points-for-first-quarter\" target=\"_blank\">FQ1</a> revenue from the North American towable ($1.20B) and North America motorized ($416M) businesses ahead of expectations, while the European RVs business revenue ($493M) came in below consensus.</li> <li>Gross margin was reported at 14.3% of sales vs. 11.8% a year ago. Favorable overall product mix and reductions in material, labor and warranty cost percentages in the North American RV segment were offset only partially by the gross profit margin from the European RV segment.</li> <li>\"We are optimistic about our prospects for improved results in FY20, particularly following such a solid start to the fiscal year. Attendance and feedback from recent shows in Düsseldorf, Germany; Hershey, Pennsylvania; Fontana, California; and our Open House in Elkhart, Indiana, have been very positive,\" says CEO Bob Martin.</li> <li>\"Consistent with our comments from last quarter, our outlook for North American markets is to remain relatively flat, or decline modestly, in fiscal 2020, barring a significant macroeconomic change, with the potential for better results should retail demand strengthen. For the European retail market, we expect to see modest growth similar to fiscal 2019.\"</li> <li>Shares of Thor Industries are <font color=\"green\">up 1.79%</font> in premarket trading to $68.98.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3524679-thor-eps-beats-0_26-misses-on-revenue\" target=\"_blank\">Thor EPS beats by $0.26, misses on revenue</a> (Dec. 9)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524705\" data-linked=\"Thor Industries +2% after posting margin improvement\" data-tweet=\"$THO - Thor Industries +2% after posting margin improvement https://seekingalpha.com/news/3524705-thor-industriesplus-2-after-posting-margin-improvement?source=tweet\" data-url=\"https://seekingalpha.com/news/3524705-thor-industriesplus-2-after-posting-margin-improvement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524698\" data-ts=\"1575894552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORLY\" target=\"_blank\">ORLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524698-oreilly-automotive-slips-after-goldman-sachs-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">O&#39;Reilly Automotive slips after Goldman Sachs cut</a></h4><ul> <li>Goldman Sachs lowers O'Reilly Automotive (NASDAQ:<a href='https://seekingalpha.com/symbol/ORLY' title='O&#39;Reilly Automotive, Inc.'>ORLY</a>) to a Neutral rating from Buy.</li> <li>The firm assigns a price target of $479 to O'Reilly vs. the <a href=\"https://seekingalpha.com/symbol/ORLY/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $455.35.</li> <li>Shares of ORLY are <font color=\"red\">down 1.27%</font> in premarket trading to $439.90</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524698\" data-linked=\"O&#39;Reilly Automotive slips after Goldman Sachs cut\" data-tweet=\"$ORLY - O&#39;Reilly Automotive slips after Goldman Sachs cut https://seekingalpha.com/news/3524698-oreilly-automotive-slips-after-goldman-sachs-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3524698-oreilly-automotive-slips-after-goldman-sachs-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524696\" data-ts=\"1575894276\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FATE\" target=\"_blank\">FATE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524696-fate-therapeutics-up-23-premarket-on-encouraging-data-on-multantigen-car-t\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fate Therapeutics up 23% premarket on encouraging data on multantigen CAR T</a></h4><ul><li>Fate Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FATE' title='Fate Therapeutics, Inc.'>FATE</a>) is up <font color=\"green\">23%</font> premarket on light volume in reaction to <a href=\"https://seekingalpha.com/pr/17721392-fate-therapeutics-announces-new-preclinical-data-for-ft596-off-shelf-ipsc-derived-car-nk-cell\" target=\"_blank\">positive preclinical data</a> on FT596, the first multantigen CAR T-cell immunotherapy candidate to be cleared for clinical trials in the U.S. The data were presented at ASH in Orlando.</li><li>Results from a humanized mouse model of CD19-positive lymphoma showed a durable anti-tumor effect and extended survival similar to primary CAR T cells. When combined with rituximab (Roche's Rituxan), FT596 showed enhanced killing of CD20-positive lymphoma cells compared to rituximab alone.</li><li>In preparation of the start of Phase 1 development, it recently completed a small-scale production run of 300 cryopreserved infusion-ready doses at a cost of ~$2,500 each.</li><li>FT596 is an off-the-shelf natural killer &#40;NK&#41; cell immunotherapy derived from a clonal master induced pluripotent stem cell line engineered with three anti-tumor functional modalities (current patient- and donor-specific CAR T therapies recognize only one antigen).</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3524696\" data-linked=\"Fate Therapeutics up 23% premarket on encouraging data on multantigen CAR T\" data-tweet=\"$FATE - Fate Therapeutics up 23% premarket on encouraging data on multantigen CAR T https://seekingalpha.com/news/3524696-fate-therapeutics-up-23-premarket-on-encouraging-data-on-multantigen-car-t?source=tweet\" data-url=\"https://seekingalpha.com/news/3524696-fate-therapeutics-up-23-premarket-on-encouraging-data-on-multantigen-car-t\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3524690\" data-ts=\"1575893280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/M\" target=\"_blank\">M</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3524690-macysminus-3-after-goldman-sachs-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macy&#39;s -3% after Goldman Sachs cut</a></h4><ul> <li>Shares of Macy's (NYSE:<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s, Inc.'>M</a>) break lower after Goldmans Sachs drops the department store stock to a Sell rating after having it slotted at Neutral.</li><li>The firm doesn't see significant upside value creation from more real estate plays.</li> <li>Goldman's price target of $12 on Macy's reps more than 20% downside potential and is below the <a href=\"https://seekingalpha.com/symbol/M/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $16.19.</li> <li>Macy's is <font color=\"red\">down 2.71%</font> in premarket action to $14.74.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3524690\" data-linked=\"Macy&#39;s -3% after Goldman Sachs cut\" data-tweet=\"$M - Macy&#39;s -3% after Goldman Sachs cut https://seekingalpha.com/news/3524690-macysminus-3-after-goldman-sachs-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3524690-macysminus-3-after-goldman-sachs-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>79&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}